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Abstract 
Traumatic brain injury (TBI) is clinically divided into a spectrum of severities, with mild 
TBI being the least severe form. Mild TBI is caused by blunt non-penetrating head trauma 
that causes stretching and tearing of axons, the long neuronal extensions, with diffuse 
axonal injury (DAI) being the central pathogenic mechanism. Mild TBI is basically 
synonymous with concussion; both are defined on pure clinical grounds in different 
consensus criteria that are largely compatible. Symptoms in mTBI are highly variable; loss 
of consciousness may, or may not, be present. There are no validated imaging or fluid 
biomarkers to identify (or rule out) whether a patient with a normal CT scan has neuronal 
damage. While most patients recover quickly from mTBI, others report persistent 
symptoms, a condition called post-concussive syndrome (PCS). The pathophysiology 
underlying PCS, and the relative importance of the severity of neuronal damage and 
psychosocial factors for its development, are largely unknown. Repeated concussive and 
sub-concussive head injuries have been linked to the neurodegenerative condition chronic 
traumatic encephalopathy (CTE), which has been reported in a series of contact sports 
athletes sports and in some soldiers exposed to explosive blasts. Hyperphosphorylation and 
aggregation of the neuronal protein tau is suggested as the key pathological finding in 
CTE. Modern MRI techniques to  identify and grade axonal injury and PET methods for 
tau and amyloid pathology show promise as diagnostic tools for CTE. Longitudinal clinical 
studies employing such techniques are needed to learn what percentage of contact sport 
athletes will develop CTE, and what number and severity of concussive events that are 
required for developing this disorder. Given that CTE mainly affects contact sport athletes, 
and is believed to be due to repetitive head trauma, unique opportunities for prevention by 
rule changes are open for discussion by sports organizations and legislators. 
 
 [H1] Introduction 
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Traumatic brain injury (TBI) affects people of all ages and is recognized as a major cause 
of death and disability worldwide1. TBI can be categorized into mild, moderate and severe, 
largely based on clinical variables such as duration of unconsciousness (if present), 
amnesia and neurological symptoms2 (Box 1). Moderate and severe TBI are neurosurgical 
and intensive care concerns; the focus of this Primer article is concussion or mild TBI, 
which represent 80-90% of all cases3, and how mild TBI may increase the risk of long-
term and sometimes progressive neurologic disease.  
 
Mild TBI and concussion are interchangeable terms for the mildest form of TBI, both 
defined purely on clinical grounds, and conceptualized in clinical criteria outlined by 
different working groups, that largely are compatible with each other.3-5 In short, mild TBI 
is typically caused by blunt non-penetrating head trauma and results in transient symptoms. 
6Symptoms (clinical observations and often patient self-reporting) in mild TBI are highly 
variable, and can, except for loss of consciousness (not a prerequisite), include physical 
(e.g., nausea and vomiting, dizziness, headache), cognitive (e.g., poor concentration and 
memory problems), and behavioral (e.g., irritability, and emotional lability) symptoms4. 
According to the American Congress of Rehabilitation Medicine (ACRM) criteria,4 
computerized tomography (CT) of the brain, as well as a routine neurological examination, 
may (or may not) be normal.4  loss of consciousness (if present) should be less than 30 
min, at which time the Glasgow Coma Scale (GSC) score should be 13-15, and 
posttraumatic amnesia (if present) should not exceed 24 hours, for a TBI to be classified as 
mild. It is generally agreed across criteria that there is no single test to assist making a 
clinical diagnosis of mild TBI.  
 
Mild TBI 5symptoms resolve within 7-10 days in the majority (80–90%) of cases. Most 
patients who exhibit post-concussive symptoms following a mild TBI show symptom 
resolution within 1-12 weeks. The recovery period after sports concussion may be shorter 
since athletes typically are in better physical condition than patients evacuated to 
emergency centers for non-sports mild TBI, who more frequently have pre-existing 
behavioral, psychiatric, and/or substance abuse problems that increase their susceptibility 
to injury and may prolong recovery6, 7, although an alternative explanation may be that 
sports-related TBIs result from lower mechanical forces.   However, those who have 
persisting symptoms are said to have post-concussive syndrome (PCS)8. The symptoms of 
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PCS are highly variable (Box 2), which also makes its exact prevalence difficult to 
estimate; 10-15% is probably a reasonable inference8.  
 
Chronic traumatic encephalopathy (CTE) has garnered much recent attention as a long-
term consequence of repeated mTBIs and repetitive sub-concussive head impacts, 
particularly in contact sport athletes and military veterans. First described by Martland9 in 
1928 as “punch drunk syndrome” in retired boxers, the condition has also been called 
“dementia pugilistica”10 before being referred to as CTE in the 1940s11-13.  
 
Neuropathologically, CTE has been associated with widespread neurofibrillary tangles in 
several brain regions14. Widespread amyloid plaques, similar to those in Alzheimer’s 
disease, may be found in approximately 50% of CTE cases, and are significantly 
associated with age and the inheritance of the apolipoprotein E (APOE) ε4 allele15. 
_ENREF_17In 2005, the first case report on CTE in a former American football player 
was published16, and after that CTE pathology has been identified in several other contact 
sports, such as ice hockey, wrestling and rugby, and also in soldiers exposed to explosive 
blasts, although the number of cases is limited17. At present, CTE is a neuropathological 
diagnosis requiring post-mortem examination, given that there are no established or 
validated clinical criteria and no biomarkers to support the diagnosis ante mortem.  
 
In this Primer article, we give a comprehensive update on mild TBI and concussion in 
adults, together with the relation to its possible sub-acute and long-term consequences, 
PCS and CTE. In this review, we regard TBI as a spectrum of severities, with mild TBI 
being the least intense, instead of clear-cut entities. An exception is the addition of other 
types of injuries (contusions, bleedings) in the severe forms, due to the more extensive 
mechanical forces involved. We find it unlikely that there is any pathophysiologic 
distinction between the different TBI severities, and instead plausible that the same 
underlying cellular and molecular processes are involved, just to different degrees.  
 
  
[H1] Epidemiology 
TBI is a leading cause of disability and death with almost 10 million people affected 
worldwide each year18. A recent meta-analysis from 16 European countries estimates that 
the incidence of hospital-admitted TBI cases is 262 per 100,000.19.The Centers for Disease 
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Control and Prevention in the United States report an increase from 567 to 824 per 100,000 
TBI-related emergency department visits between 2000 and 201020. The incidence of TBI 
has increased in middle and low-income countries. 21The true incidence of TBI is likely 
higher given that mild TBI cases, which probably account for 70-90% of all cases, are 
underestimated in most studies1. A large statewide population-based study reported that 
more than 40% of participants had at least one TBI during lifetime.22 
 
The most common causes of TBI of any severity are falls and traffic injuries, which 
together account for more than 50% of cases.19, 20, 23 Rates of TBI tend to be higher among 
men compared to women with the peak incidence among adults in the oldest age groups.19, 
20, 23 Surveillance data suggests that the incidence of sports-related TBI visits to emergency 
rooms in the USA is 152 per 100,000, with almost two-thirds occurring in children and 
young adults <19 years of age, with numbers growing in both males and females.24 In 
addition, military service members represent a unique risk group.  
 
Epidemiological studies show that negative outcomes (disability, poor life satisfaction, and 
memory impairment) increase in prevalence with increasing TBI severity.22 Such studies 
also suggest an association between TBI and risk of dementia. A meta-analysis of 15 case–
control studies reported an increased odds ratio (OR) of 1.58 (95% CI 1.21-2.06) for the 
association between head injury and risk of Alzheimer’s disease. 25 26-28However, it should 
be noted that these studies are based on clinically diagnosed Alzheimer’s disease patients, 
which is known to be unreliable also in memory clinic settings; the studies did not include 
autopsy or biomarker (amyloid PET or CSF A and tau) assessed cases. Therefore, the 
type of dementia associated with TBI is unclear. 25, 28, 2926, 28Further, although several 
studies have demonstrated a dose–response effect such that risk of dementia increases with 
increasing severity of TBI,26, 27 the risk associated with mild TBI is unknown.28 
Investigation of mild TBI effects may be particularly difficult as mild TBIs are 
underreported and the definition of mild TBI is often not uniform across studies.28  
 
Epidemiological evidence is also incomplete for the risks associated with repetitive TBIs 
and CTE. Although cognitive and behavioral changes are reported among contact sports 
athletes who experience repetitive head injuries,29 there are no estimates for prevalence or 
incidence. A limitation is that no imaging or fluid biomarkers are available to identify CTE 
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clinically, and differentiate this disorder from AD or other neurodegenerative diseases. 18, 
31 
 
[H1] Mechanisms/pathophysiology 
[H2] Biophysical mechanisms 
Improved understanding of how the physical forces from an external blow to the head are 
transmitted and transduced in the brain should shed light on how physiological functions 
are affected and pathogenic processes of TBI are initiated.  
 
Brain damage in TBI is caused by rotational (angular) and/or linear (translational) 
acceleration forces or by blunt trauma with impact deceleration (Figure 1). Such 
acceleration and deceleration forces generate intracranial pressure gradients through the 
inertia of the brain that lags behind the skull during the rapid movement. As a result, axons 
are stretched and damaged leading to diffuse axonal injury (DAI)30. Whether different 
types of acceleration and deceleration forces cause axonal damage by different 
mechanisms is unclear; either focal strains (because the brain cannot rotate within the 
skull) or strains owing to differences in densities between brain tissues at different sites 
(e.g. the cortex and the underlying white matter) might be at play31. Indeed, biomechanical 
studies show that morphologic heterogeneity of the cortex is important in diffuse brain 
injury; higher stress and strain forces are evident in the bottom of the sulci in the cerebral 
cortex32, matching tau pathology in CTE, which is localized to these cortical structures33. 
 
Exactly how the shearing forces cause the axonal damage is not known. However, the 
severity of DAI is directly proportional to the severity of brain injury as measured by the 
severity of symptoms and functional outcomes, and occurs after brain 
acceleration/deceleration forces are applied — not secondary to other types of injury such 
as ischemia or inflammation34. Concussions in contact sports are also related to the forces 
of the head impacts. In American football, concussions are related to the degree of head 
acceleration from the impacts35. In boxing, the rotational acceleration due to a punch 
increases in heavier weight class36, which is easy to imagine given that it has been 
estimated that a punch by a professional boxer generates the same force on impact as being 
hit in the head by a 6 kg bowling ball rolling at 20 mph37.  
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[H2] Neuropathology 
[H3] Pathology of acute mild TBI  
Neuropathological changes found after concussion and other forms of mild TBI include 
mild multifocal axonal injury, microglial activation and microhaemorrhages.38, 39 The 
multifocal axonal injury typically involves the fornices, corpus callosum, subcortical 
white matter and cerebellum.40 Less consistent findings include TDP-43 immunopositive 
neurites, whereas cytoplasmic neuronal TDP-43 inclusions are not found until later stages, 
and small focal accumulations of paired helical filament (PHF)-tau, either as NFTs or 
neuropil threads.40  
 
[H3] Pathology of mild CTE  
Neuropathology of CTE includes both gross alterations, with cavum septum pellucidum or 
septal fenestrations being common pathological findings, and microscopical changes in the 
form of accumulation of (PHF)-tau aggregates in neurons and astroglia, neurofibrillary 
tangle formation, astrocytic inclusions and dot-like and spindle shaped neurites.33 Tau 
abnormalities are most often distributed around small blood vessels at the depths of 
cortical sulci and in an irregular pattern, and have a tendency to involve the superficial 
cortical layers (Figure 2).33 Indeed, this pathognomonic lesion distinguishes CTE from 
other neurodegenerative tauopathies, including Alzheimer’s disease, progressive 
supranuclear palsy, agyrophilic grain disease, corticobasal degeneration, primary age-
related tauopathy (PART), parkinsonism dementia complex of Guam (GPDC) and non-
specific tau astrogliopathy (ARTAG).39, 41 _ENREF_45A staging scheme of progressive 
PHF-tau pathology with four stages (stage I-IV) has been proposed that will be important 
for future studies on CTE prevalence and its relation to number and severity of repeated 
TBIs.42  
 
Other abnormalities in CTE include deposits of phosphorylated 43-kDa TAR DNA-
binding protein (TDP-43) protein in the majority (80%) of cases that occasionally co-
localized with PHF-tau, axonal dystrophy and neuroinflammation.42, 43 In addition, around 
A) as either diffuse or neuritic plaques, 
and a proportion (14%) meet the criteria for Alzheimer’s disease.15 When compared to an 
autopsy community cohort, the deposition of A was altered and accelerated in CTE such 
that CTE subjects were overall 4-fold more likely to have A plaques and developed 
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plaques 10-15 years earlier. Moreover, A plaques were significantly associated with more 
severe PHF-tau and Lewy body pathology and worse clinical outcome independent of the 
effect of age. 
 
Recent neuropathological studies indicate that CTE pathology may be common among 
contact sport athletes.44 However, further studies are necessary to clarify what proportion 
of athletes develop this type of pathology and how many become symptomatic, as well as 
how many athletes escape CTE pathology despite repeated concussions.  
 
[H2] Cellular and molecular pathophysiology  
[H3] Axonal injury  
 Studies of the molecular pathophysiology of TBI have examined many domains including 
neuronal cell death, astroglial injury, astroglial and microglial responses, dendritic injury, 
and synaptic dysfunction. Notably, though, much of the field has focused on the topic of 
axonal injury (Figure 3), largely because of clinical and experimental observations linking 
the severity of axonal injury to the extent of disability following TBI45. For example, 
axonal injury is consistently revealed by amyloid precursor protein (APP) 
immunohistochemistry (APP undergoes fast axonal transport and accumulates at sites of 
axonal injury with transport failure) in every TBI of all severities, ranging from concussion 
(with death from other causes) to severe TBI 46, 47. In a non-human primate TBI model, the 
depth of coma following rotational acceleration injury was directly proportional to the 
extent of axonal injury in the brainstem 34. Similar observations were subsequently 
reported in a pig model 48. Using non-invasive imaging methods such as diffusion tensor 
MRI and fluid biomarker-based measurements of axonal injury-related proteins, several 
investigators have demonstrated correlation between axonal injury severity and outcomes 
in patients with mild TBI and in patients with more-severe injuries.49, 50 Thus, the focus on 
axonal injury seems to be well justified by the clinical literature. 
 
Axonal injury can be detected immediately after injury when forces of sufficient 
magnitude are applied to the brain. Electron microscopic analyses indicate that 
microtubules are disrupted within 2 minutes after a rapid stretch of the axons of cultured 
neurons 51. Subsequently, axonal varicosities (distorted and irregular axonal swellings or 
local dilations) form, apparently due to failed axonal transport along the disrupted 
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microtubules. Indeed, these varicosities are the most common form of axonal injury and 
show accumulation of APP due to disturbed axonal transport. Similar axonal varicosities 
are a hallmark of traumatic axonal injury observed after TBI in human patients.52, 53 Axons 
in general, and microtubules specifically, may be more mechanically brittle than other 
structures in the nervous system, although this idea has not been rigorously tested. 
Dynamic instability may also contribute to microtubule disruption and failed axonal 
transport in TBI 51.  
 
Subsequent investigations have revealed other forms of axonal injury54, 55. For example, 
cytoskeletal neurofilament compaction has been observed by electron microscopy and 
immunohistochemistry using antibodies recognizing neurofilament neo-epitopes56, 57. The 
mechanisms underlying this neurofilament compaction include disruption of the integrity 
of the plasma membrane leading to increased intracellular calcium, activation of calpain 
and caspase, and cytoskeletal proteolysis including spectrin and neurofilament side arm 
cleavage.58 Another form of axonal injury involves collapse, rather than dilation. Such 
injury has been detected by electron microscopy after experimental concussion59. The 
mechanisms underlying axoplasmic collapse remain to be determined.  
 
Importantly, not all forms of axonal injury result in disconnection of axons60; injured axons 
can remain connected at least over the time span of the observations, although whether 
these injured but still connected axons are functional remains to be determined. Notably, 
the extent of traumatic axonal injury can be greatly underestimated in studies based on 
conventional thick-section light microscopic histopathology, which is only capable of 
visualizing dilated axons and axonal varicosities. Non-dilated, injured axons cannot be 
resolved with conventional histopathology, but instead require electron microscopy or 
ultrathin section-based approaches61. To our knowledge, super-resolution light microscopic 
studies of injured axons have not yet been reported.  
 
 
A is a key component of plaques in Alzheimer’s disease, and is produced by sequential 
cleavage from APP by -secretase (BACE1) and the γ-secretase complex (with presenilin 
constituting the active site).62 Epidemiological studies suggest a link between TBI and risk 
of late life dementia in general, and of Alzheimer’s disease in particular. There are two 
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major hypotheses regarding the mechanisms underlying this increased risk63; the first is 
that TBI reduces cognitive reserve such that the same pathophysiological processes 
underlying Alzheimer’s disease cause detectible symptoms at an earlier age, leading to a 
net increase in prevalence of dementia. The second hypothesis is that TBI directly sets into 
motion the tau and A pathophysiological processes underlying Alzheimer’s disease. 
These two hypotheses are not mutually exclusive.  
 
Evidence to support the accelerated A hypothesis includes the findings of diffuse A 
plaques in a subset of human patients with severe TBI at younger ages than would be 
expected.64, 65 -axonal 
deposition of A66. The origin of the extracellular plaques is unknown; microdialysis-
but instead decreases acutely after TBI and then recovers as neurological function is 
restored, likely due to recovery of synaptic activity 67, 68. A similar recovery phase may 
explain the delayed rise in A observed in ventricular cerebrospinal fluid in patients with 
acute TBI69. In contrast, acutely elevated A levels have been observed in tissue lysates 
following experimental injury70; the reasons for this discrepancy may have to do with 
partial mixing of increased intracellular and decreased extracellular A pools in tissue 
lysates68. The increase in intra-axonal A is believed to arise from the aberrant co-
localization of APP, the -secretase complex, and the -secretase BACE1 at the sites of 
failed axonal transport 71. Inhibition of -secretase prevents TBI-related intra-axonal A 
formation in mice, but does not seem to affect the overall severity of axonal injury 72. 
Recent work on the pathophysiology of age-related Alzheimer’s disease has emphasized 
the role of soluble oligomeric assemblies of A 73, 74 as key mediators of the synaptic 
dysfunction and memory loss that underlie Alzheimer’s disease 75-78. However, the effects 
of TBI on A oligomers remain to be determined. Thus, TBI has complex and 
incompletely characterized effects on A. 
 
[H3] Tau aggregation  
Tau aggregation has been observed in a subset of TBI patients, most commonly in those 
with CTE. Tau is a microtubule-stabilizing protein, and it has been hypothesized that up-
regulation of tau may be an aberrant attempt to stabilize microtubules disrupted by the 
trauma. An alternative hypothesis is that aberrant phosphorylation of tau leads to loss of its 
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normal microtubule-binding function and promotes its aggregation. In other contexts, A 
aggregates may induce tau phosphorylation and aggregation 79; however, in the setting of 
experimental TBI, 90% reduction in A levels had no effect on TBI-related tau 
aggregation 72. In contrast, c-jun N-terminal kinase (JNK) activation was co-localized with 
tau aggregates, and JNK inhibition reduced TBI-related tau aggregation 80. Thus, the 
mechanisms underlying TBI-related tau aggregation may be distinct from the mechanisms 
elucidated in other contexts. 
 
[H3] Other types of pathophysiological changes  
The inflammatory responses to TBI are major pathophysiological events that may affect 
outcomes in complex ways. Microglia, the resident innate immune cells in the brain, are 
dramatically activated in the first days to a week after injury and can either be transient or 
persistent.81, 82 However, the mechanisms underlying microglial activation, their effects on 
debris removal, repair, recovery, progressive degeneration and long-term 
neurodegenerative sequelae remain to be determined 83. Furthermore, the current 
categorization of microglia into M1 “classically activated” and M2 “alternatively 
activated” sub-types may be inadequate for characterization of responses to TBI 84. Soluble 
cytokine response is also quite dramatic in human TBI patients 85, further supporting that 
inflammation may be a therapeutic target, at least in severe TBI 86. After TBI, free radical 
stress in the form of high levels of oxidized and nitrosylated proteins, lipids and nucleic 
acids can be detected in the brain. Early free radical stress may be due to e.g. the 
arachidonic acid cascade, mitochondrial dysfunction, and nitric oxide synthase activation 
in severely injured portions of the brain 87 but is not as clearly involved in less severely 
injured areas or in concussive injury. Specific mitochondrial lipid oxidation has recently 
been demonstrated, and may play an important role in apoptotic cell death 88. The effects 
of delayed free radical stress from microglial and other inflammatory cellular responses is 
just beginning to be explored 89. In summary, the role of inflammation in TBI warrants 
further study, especially to elucidate what are the various roles for microglial activation 
after TBI, and which roles are beneficial and which are harmful, with regard to clearance 
of debris and promoting recovery.  
 
[H2]Genetic factors 
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Genetic factors may influence both short-term survival and long-term neurological and 
functional outcome after TBI by affecting several different putative pathogenic pathways. 
Short-term survival may depend on gene variants influencing the severity of axonal 
damage, or other processes such as inflammation or blood-brain barrier disruption, 
whereas long-term outcome may depend on genes involved in neuronal regeneration and 
plasticity. Some studies have found associations between polymorphisms in genes 
involved in neuronal plasticity, e.g. the brain derived neurotrophic factor (BDNF) gene, 
and inflammatory response, e.g. the interleukin (IL) genes90. In general, studies examining 
potential associations between gene polymorphisms and TBI outcome are hampered by 
difficulties in dividing cohorts with highly variable brain damage into groups with 
comparable injuries due to the lack of biomarkers to measure the severity of neuronal 
damage, and also that outcome is measured using relatively crude rating scales or other 
outcome measures.  
 
The most examined susceptibility gene for short and long-term prognosis after TBI is the 
apolipoprotein E gene (APOE). The APOE gene encodes for a protein involved in 
cholesterol and lipid metabolism, and is a main component of plasma lipoproteins. ApoE is 
also the principal apolipoprotein in the CNS, where it is involved in neuronal repair 
through recycling of cell membrane lipids to build new cell neuronal membranes, neurites 
and synapses during regeneration in response to brain injury91, 92.  
 
The APOE gene is polymorphic, with three alleles called APOE ε2, ε3, and ε4, with the ε3 
allele being most common in the population. The APOE ε4 allele is a well-established and 
strong susceptibility gene for Alzheimer’s disease62, affecting both disease risk and age at 
onset, but has also been suggested to influence prognosis or rate of progression of several 
other brain disorders93. An association between poor short-term clinical outcome after TBI 
and the APOE ε4 allele has been found in some studies, but associations are weak and 
variable and several studies report no effect90. Preclinical studies on experimental TBI 
suggest that ApoE may affect the severity of axonal injury; mice with the ε4 allele showed 
larger numbers of dilated, APP stained axons than ε2 or ε3 mice94. Further, several clinical 
studies suggest that possession of the APOE ε4 allele predicts poor long-term (6-12 
months) clinical outcome after TBI, as also verified in a recent meta-analysis that showed 
an effect especially in severe TBI cases95.  
 
13 
 
Studies examining the APOE gene in relation to CTE are scarce. The first indication for an 
association was a study on retired professional boxers with high exposure to head-blows in 
which ε4 carriers had more severe symptoms of chronic brain injury96. Further support for 
an effect of the APOE gene on CTE risk include a study finding lower cognitive 
performance in older football players carrying the APOE ε4 allele97, and a small 
neuropathological series of 10 CTE cases showing a high (50%) proportion of APOE ε4 
carriers33. The mechanisms underlying the putative association between the APOE gene 
and CTE risk may involve isoform-dependent effects on neuronal regeneration and 
plasticity or may be linked to build-up of tau or Aβ pathology. In Alzheimer’s disease, the 
leading hypothesis is that Aβ aggregation and clearance are differentially regulated by the 
ApoE isoforms98. Considering that amyloid plaques are found only in later stage CTE 
cases33, mechanisms related to β-amyloidosis are unlikely to be involved in initiating the 
disease. Further large clinical studies applying consensus criteria for the clinical diagnosis 
of CTE as well as biomarkers to subgroup cases with brain amyloidosis and tauopathy are 
warranted to verify and explore the mechanisms for the association between APOE and 
CTE, and to identify novel risk genes. 
 
[H1] Diagnosis, screening and prevention 
[H2] TBI severity  
Acute TBI severity is classified primarily by level of consciousness measured by the 
lowest post-resuscitation Glasgow Coma Scale (GCS) score99. This score consists of 
graded responses to behaviors (eye opening, and verbal and motor responses to questions 
and pain stimuli). However, since some components of the GCS scale may be untestable 
(if, for example, the patient is intubated) or cannot be tested reliably, clinicians are 
recommended to report subscale scores for individual patients100. For use in the clinical 
setting, clinicians should, however, consider brain imaging, neurophysiological measures, 
other neurological findings such a pupillary response, and fluid biomarkers in addition to 
the GCS score in classification of TBI, monitoring clinical management, and prognosis100.  
 
 
[H2]Clinical characteristics of PCS and CTE  
Patients having symptoms persisting several months after mTBI are classified as having 
post-concussive syndrome (PCS). However, PCS is a difficult diagnosis since there are no 
objective diagnostic tools. In addition, PCS symptoms, such as headache, fatigue, sleep 
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disturbances and anxiety, are common in everyday life in healthy people, especially in 
persons with pre-existing psychiatric conditions such as anxiety and depression. Further, 
symptoms are influenced by personality and psychological8 and demographic factors such 
as social status, sex, ethnicity and alcohol use,101 that also may affect rate of recovery after 
mild TBI.  
 
CTE is also ambiguous to diagnose clinically, due to varying clinical features and lack of 
established biomarkers to support a clinical suspicion of the disease. Clinical criteria for 
the diagnosis of traumatic encephalopathy syndrome (TES), the clinical counterpart of 
CTE, have been defined and are currently undergoing evaluation in a large longitudinal 
study102.  
 
Individuals who develop CTE tend to have begun their sport early, and while symptoms at 
varying ages, one third are symptomatic at the time they retire from the sport, and in most 
cases the condition advanced slowly over several decades33. Retrospective descriptions of 
symptoms suggest three primary subtypes: behavioral/mood changes (irritability, 
depression, sleep disturbance), cognitive deficits (poor attention, memory problems, 
executive dysfunction, dementia) and a mixed feature subtype102. Motor deficits 
(Parkinsonism, ataxia, dysphasia) have also been described in former boxers with the 
dementia pugilistica CTE variant14. Pending results of current prospective, longitudinal 
studies of at-risk athletes with a control group, these descriptions should be interpreted as 
preliminary, for further details on sports-related concussion, see Box 3. 
 
[H3]Endocrine complications  
The most common endocrine complications following TBI are related to injury to the 
pituitary gland. The gland itself is well protected within the sella turcica of the sphenoid 
bone; however, the pituitary stalk, connected to the anterior pituitary gland and 
hypothalamus, is vulnerable to the mechanical forces of TBI. Post-traumatic 
hypopituitarism (PTHP) is found in around 30% of TBI patients, with higher prevalence in 
more severe cases 103. The most common abnormalities are growth hormone (GH) 
deficiency and hypogonadism, whilst adrenocorticotrophic hormone (ACTH) and thyroid-
stimulating hormone (TSH) deficiencies are diagnosed less often104, 105. Almost 50% of 
TBI patients have anti-diuretic hormone deficiency severe enough to cause central diabetes 
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insipidus in the acute phase following the injury, but this deficiency often resolves within 3 
months105, 106.  
 
PTHP can result in a multitude of acute and chronic symptoms 107. For example, GH 
deficiency may result in changes in body composition and a reduction in quality of life 
including depression, whilst hypothyroidism may cause weight gain, low mood and 
blunted cognition 107. Most crucially, acute adrenal insufficiency may occur within days of 
TBI in some patients, with the ensuing adverse consequences of hypotension, 
hyponatraemia and hypoglycaemia, which require emergent treatment. PTHP is also 
relevant in the context of mild TBI; a recent study demonstrated a prevalence of GH 
deficiency of 1% in a cohort of patients with a history of concussion 108 and even higher 
prevalence has been reported in athletes with a history of repetitive head trauma 107. For 
example, high prevalence (25-30%) of hypopituitarism with GH and ACTH deficiency has 
been reported in amateur kick boxers and retired American football players that may result 
in poor quality of life, erectile dysfunction and metabolic syndrome109, 110. Likewise, as 
many as 42% of military personnel with previous blast-related mTBI had abnormal 
hormone levels in one or more pituitary axes111. Given the subtle nature of some of the 
symptoms, screening strategies in patients with a history of TBI were recently proposed 112, 
113. 
 
[H2]Imaging 
CT scans are fast, accurately detect essentially all life-threatening and surgically treatable 
intracranial hemorrhages in TBI patients114. However, CT scans do not detect axonal injury 
and provide only modest information regarding prognosis. Indeed, even if CT is part of the 
diagnostic criteria, many patients with mild TBI evaluated in the emergency department 
and most cases of sports concussion do not undergo any structural brain imaging. Further, 
it has been reported that 28% of patients with normal CT have lesions on MRI performed 
in the research setting within 2 weeks of the trauma, with lesions (contusions and/or 
multiple foci of hemorrhagic axonal injury) being associated with worse outcome115. 
 
[H3] MRI-based techniques  
MRI scans provide superior anatomical detail over CT, more sensitive detection of smaller 
hemorrhages, and improved information regarding prognosis 114-116. However, MRI is less 
clinically available and has longer scan times. Further, conventional MRI sequences 
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provide little ability to resolve axonal injury (Figure 4), and most concussive TBI patients 
have normal conventional MRI scans, even though they often have other evidence of 
traumatic axonal injury. For this reason, extensive efforts have gone into developing 
improved MRI sequences that are more sensitive to axonal injury. 
 
Diffusion tensor imaging (DTI) is the leading MRI sequence for the detection of axonal 
injury (Figure 4).50, 117 DTI measures diffusion of water in many directions, and from these 
measurements, the directional asymmetry, termed anisotropy, of water diffusion can be 
calculated. Injured axons have lower anisotropy, and in experimental animal the extent of 
reduced anisotropy quantitatively correlates strongly with the extent of axonal injury 
measured by immunohistochemistry.114, 118 Reduced anisotropy after TBI has been reported 
in a large number of clinical studies of patients with many types of TBI, at a variety of 
time points after injury even when CT and conventional MRI showed no evidence of 
injury.117, 119 Reductions in anisotropy in specific white matter tracts was found to correlate 
with TBI-related cognitive deficits 120, and to the neuronal protein tau measured in 
microdialysis fluid 121. Limitations of DTI include its relative insensitivity to injury in 
complex white matter regions, inconsistencies in the literature concerning the direction of 
change in anisotropy after mTBI, and lack of spatial resolution to detect injury in small 
white matter tracts 122. Furthermore, DTI needs standardization across different scanners, 
making it necessary to obtain control data on each scanner for each study. Novel diffusion 
imaging methods such as diffusion kurtosis imaging 123, high angular resolution diffusion 
imaging 124, high definition fiber tracking 125, and diffusion spectrum imaging 126 may be 
even more sensitive to axonal injury. Magnetic resonance spectroscopy is capable of 
resolving alterations in brain metabolism after TBI, and good correlations between 
metabolite concentrations and outcomes have been reported.127, 128 Functional MRI (fMRI) 
scans also reveal changes after TBI, with areas of either reduced or increased activation, 
and altered connectivity.129  
 
Magnetoencephalography (MEG) detects changes in magnetic fields caused by brain 
electrical activity. Time resolution of MEG is orders of magnitude better than fMRI, 
allowing resolution of fast activity and transient changes in functional connectivity. MEG 
may detect abnormalities following TBI that were not identified with DTI or conventional 
MRI, and may correlate with clinical outcome.130, 131 130-133. However, MEG is available 
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only at a few centers, similar to DTI has limited spatial resolution, and cannot yet be 
readily standardized between sites. 
 
[H3]PET 
PET ligands have been developed that bind to aggregated Aβ and give a measure of the 
amount of amyloid deposits in different brain regions as compared with cerebellum that is 
used as a reference region. Alzheimer’s disease patients typically show a 50-70% increased 
ligand retention in cortical brain regions as compared that found in elderly controls134. 
Except for the 11C-labelled amyloid ligand PiB, which has a short half-life that hinders its 
use outside specialized research centers with access to an on-site cyclotron, 18F-labeled 
tracers with longer half-lives, including florbetapir, flutemetamol and florbetaben, have 
been developed for a more wide-spread use of amyloid PET.  
 
A first pilot study using PiB amyloid PET showed young to middle-aged patients with 
moderate to severe TBI had increased amyloid deposition in cortical grey matter and in the 
striatum as compared with controls in the acute period up to 1 year post-trauma135. Another 
small study on severe TBI cases examined 11-17 months after injury showed increased PiB 
retention in the precuneus/posterior cingulate and cerebellum136. Amyloid deposition in the 
posterior cingulate correlated with decreasing fractional anisotropy assessed by DTI, but 
was much lower than the amount found in Alzheimer’s disease cases136. There are no 
studies on amyloid PET in cases with mild TBI.  
 
PET using 18F-labeled fluorodeoxyglucose can measure glucose uptake and metabolism in 
different brain regions. Perturbed brain FDG-PET is found in Alzheimer’s disease, other 
neurodegenerative disorders, and psychiatric disease such as schizophrenia and bipolar 
disorders.137 The general trend for an outcome in moderate to severe TBI studies is 
increased glucose metabolism in some brain regions during the acute phase, followed by a 
prolonged hypometabolism during the sub-acute to chronic phase, while mild TBI is less 
studied and findings variable.138  
 
Recent developments have given several tau PET tracers with high binding affinity and 
selectivity to PHF-tau deposits in the brain139. Tau PET is currently being evaluated in 
Alzheimer’s disease, a show promise to monitor the development of tau pathology during 
the clinical course of the disease and to improve understanding of pathophysiology140. 
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However, there are no clinical studies on tau PET in TBI or CTE patients. Large 
longitudinal clinical studies on TBI patients and cases with PCS and suspected CTE will be 
important to learn how frequent amyloid and tau deposition are, during which phase after 
TBI these proteins deposits develop, and how they correlate with other measures of 
neuronal damage and with clinical symptoms, disease stage and prognosis. 
 
 
[H2]Fluid biomarkers 
Fluid biomarkers are objective measures of pathogenic process linked to a disease or an 
injury. For acute TBI, biomarkers can be used to grade severity of brain damage and 
predict prognosis, guide clinical management, monitor therapeutic interventions, and in 
sports-related TBI to guide return-to-play decisions. Biomarker fluids of relevance to TBI 
include cerebrospinal fluid (CSF), serum and plasma. An optimal biomarker for TBI 
should reflect the pathophysiological processes.  
 
[H3] Cerebrospinal fluid biomarkers 
CSF sampling through a ventricular catheter in patients in need of intracranial pressure 
monitoring is used in clinical proof-of-concept studies on severe TBI, to evaluate candidate 
CSF biomarkers for different pathophysiological processes and their performance to 
predict survival or long-term functional outcome. Results from such studies may guide the 
design of CSF biomarker studies on mild TBI. The high sensitivity of CSF biomarkers to 
detect even minor brain damage, in patients with negative CT/MRI scans, may give 
important knowledge on the pathophysiology of mild TBI. It may be argued that lumbar 
puncture will be difficult to implement in the clinic in the evaluation of patients with acute 
mTBI. This has been the case for CSF biomarker for early diagnosis of Alzheimer’s 
disease, but increasing scientific data supporting their high performance also for early 
diagnosis have gradually changed the situation so that these diagnostic tools are 
increasingly used for diagnostic purposes in clinical practice.141 
 
Increased CSF/serum albumin ratio, a standard biomarker of blood-brain barrier function, 
has been reported in the context of a neuroinflammatory response in patients with severe 
TBI 142, 143. In mild TBI, no such changes have been seen 144, 145, suggesting that the BBB 
remains intact or only ‘opens up’ transiently in mild TBI.  
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A large number of studies report an acute phase response within the central nervous system 
following severe TBI, which is reflected in the CSF as increased concentrations of pro-
inflammatory proteins such as IL-6, IL-8 and IL-10.146, 147  
 
The best-established CSF biomarkers for axonal injury are total-tau (T-tau) and 
neurofilament light (NF-L; a structural protein mainly expressed in large caliber 
myelinated axons) 148. Studies using ELISA show that T-tau concentrations in ventricular 
CSF correlate with lesion size and outcome in severe TBI, so that high levels indicate 
worse injury.148, 149 A recent pilot study using the enhanced immunoassay using multi-
arrayed fiberoptics (EIMAF) technique found increases in ventricular CSF in both T-tau 
and P-tau during the acute phase in a small series of severe TBI cases 150. Studies on mild 
TBI show elevated CSF concentrations of both T-tau and NF-L but the magnitude of the 
rise is larger for NF-L than for T-tau suggesting that blows to the head impact long, 
myelinated axons in the white matter more than short, non-myelinated axons in the cortex, 
which is in agreement with experimental, as well as neuroimaging and neuropathological 
studies 145, 151. 
 
NSE is a glycolytic enzyme enriched in neuronal cell bodies 152. NSE concentrations are 
higher in ventricular CSF of non-survivors following severe TBI than in survivors, and/or 
correlate with other TBI severity scores in both adults and children.153, 154 The major 
limitation of CSF NSE as a biomarker for neuronal injury is its high concentration in 
erythrocytes that may contaminate the sample 155. 
 
S-100B, an astrocyte-enriched Ca2+-binding protein has been examined extensively in 
relation to TBI in serum, while studies on CSF are rare. Amateur boxers have slightly 
elevated CSF levels after one or several bouts, but the changes are not as pronounced as 
those for the axonal markers T-tau and NF-L 151. Similar results have been reported for 
glial fibrillary acidic protein (GFAP) 145, 151, which is an intermediate filament that is 
almost exclusively expressed in astrocytes 152. However, CSF GFAP has also been 
evaluated in the context of severe TBI and ventricular levels have been shown to improve 
outcome prediction models in conjunction with clinical data 156. Further, high GFAP levels 
in blood samples may predict clinically relevant intracranial lesions in TBI patients. 157  
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Studies in both animals and humans have demonstrated that APP and A accumulate in 
neurons and axons after brain trauma with axonal damage 12. Ventricular CSF and brain 
interstitial fluid concentrations of the 40 and 42 amino acid isoforms of A increase during 
the first week of brain injury in severe TBI69, 158 and particularly in diffuse axonal injury 
159. Similar results have been obtained for soluble isoforms of APP 69. However, in studies 
of mild TBI performed on lumbar CSF samples, no amyloid-related changes have been 
seen 145, 151.  
 
The protein αII-spectrin is found in neuronal axons and presynaptic terminals in the brain 
160. αII-spectrin is proteolytically processed to αII-spectrin breakdown products (SBDPs) 
that have been suggested as potential TBI biomarkers both in animal experimental studies 
and in humans 161, 162. SBDPs have been analyzed in ventricular CSF from patients with 
severe TBI and the levels correlate with clinical correlates of the severity of the injury and 
predict outcome 156, 163, 164. In one of these studies, CSF SBDPs were evaluated together 
with another proposed TBI biomarker, ubiquitin C-terminal hydrolase-L1 (UCHL1) 156, 
which is a de-ubiquitinating enzyme highly expressed in neurons 165. The two markers 
were found to contribute clinically relevant information in addition to routine assessments. 
 
[H3]Blood biomarkers 
Based on the above, candidate blood biomarkers for TBI include NSE, UCHL1, S100B, 
GFAP, spectrin N-terminal fragments (SNTF), T-tau and NF-L. N-terminal fragments of 
α-spectrin (SNTF) accumulate in damaged axons following TBI166.  
 
Blood levels of GFAP and UCHL1 have in several studies been found to have high power 
to discriminate between patients with TBI and controls.  (Diaz 2014; Nylen 2006).167, 168 
Further, higher UCHL1 levels are found in TBI patients with abnormal CT scans, with an 
AUC value of 0.67 for UCHL1,167 and 0.88 for GFAP.169 A recent very large study on 
mild-to-moderate TBI showed AUC values of 0.80-0.97 for GFAP to detect intracranial 
lesions on CT and of 0.91-1.00 to identify patients in need of neurosurgical interventions, 
while performance was lower for UCHL1,170 another study showed similar performance to 
identify abnormal CT in mild-to-moderate TBI cases similar for all of FGAP, UCHL1 and 
S100B.171   
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There are few studies on the performance of these biomarkers in mild TBI cases, but one 
study found higher GFAP, but not for S100B, in mild TBI (GSC 13-15) in patients with 
CT abnormalities.172 Results on the performance for these biomarkers vary between 
studies. Guidelines for the use of S100B in blood for the initial management of mild TBI 
have been published,173 with the aim to reduce the number of unnecessary CT scans in 
patients at low risk for intracranial complications (and possible neurosurgical 
interventions). These guidelines were recently validated in a large multicenter study on 
mild TBI, with analyses performed using a commercial assay on a fully automated 
instrument, showing a sensitivity of 97 % and a specificity of 34 % to identify intracranial 
hemorrhage on CT scans.174  
 
SNTF is measurable in blood samples and show an increase after TBI, also in CT-negative 
mild TBI cases 175, 176, and has been suggested as a predictive marker in sports-related 
concussion 177. Standard enzyme-linked immunosorbent assays for T-tau and NF-L were 
recently transferred onto the Single molecule array (Simoa) platform, which allows for the 
ultrasensitive measurement of these two proteins in the blood 178, 179. Plasma T-tau 
concentrations correlate poorly with CSF concentrations 180, but in acute hypoxic brain 
injury the rise in plasma T-tau is predictive of outcome 178. During the acute phase of 
severe TBI, increases in serum T-tau and P-tau have also been described, with levels 
decreasing, but not down to control levels, during the period up to six months following 
the acute phase 150. In sports-related concussion, plasma T-tau has been found to predict 
return-to-play time with high accuracy 181. Serum NF-L correlates strongly with CSF NF-L 
and increases over time in American football athletes over the course of a season 182. High 
S100B levels in serum after TBI correlate with intracranial lesions detected using CT scan. 
183 For this reason, S100B in serum has been suggested as a fluid biomarker for acute TBI 
that could reduce the number of unnecessary CT scans of the brain in new clinical 
guidelines for the management of TBI 183, However, the performance of S100B in serum to 
identify minor brain injury in mild TBI cases is suboptimal 148.  
 
[H1]Management 
[H2] Acute TBI Management  
Beginning at the scene of injury and in the emergency center, urgent assessment of risk for 
an intracranial hematoma or brain swelling includes a brief interview and neurological 
examination including the GCS to determine whether a CT scan of the brain is indicated184, 
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185. Observation for 6-8 h in the emergency center and repeat assessment may be an 
alternative to CT, e.g. in patients with high GCS scores and no focal neurological signs. 
Patient and caregiver education, including verbal and written instructions for identifying 
complications, observation by an adult for 24 h, a regimen of rest (see below), and gradual 
resumption of activities is the standard of care at many centers. 
 
In PCS cases with persistent symptoms, headaches persisting >3 months, especially the 
migraine type, may respond to medication186. Depression is common secondary to 
complicated mild TBI187, and can be treated by a combination of medication and 
behavioral approaches. Instructions for good sleep hygiene are recommended because 
sleep disturbance is also a frequent sequel of mTBI185. 
 
The early post-injury period is associated with release of excitotoxic neurotransmitters, a 
neurometabolic crisis due to increased energy demand despite reduced cerebral blood flow, 
inflammation, and axonal dysfunction188. A second experimental mild TBI prior to 
resolution of the pathophysiological changes following the first injury may add cumulative 
damage and prolong recovery from the second injury as compared with spacing the two 
injuries further apart to allow the brain to recover sufficiently from the initial mild TBI.189, 
190 A case study showed evidence of ongoing neuronal damage in a knocked-out boxer for 
a period of several months.191 This window of vulnerability to re-injury has been cited as 
the rationale for prescribing rest for sports players who experience head trauma3 (Figure 5). 
 
When the athlete becomes asymptomatic at rest, light exercise and cognitive activity are 
resumed and gradually increased while monitoring symptom level. If symptoms return 
after exertion, the level of activity is reduced. Otherwise, the athlete proceeds to 
resumption of non-contact training followed by return to contact practice and competitive 
play. Time from injury to return to play (RTP) is 7 to 10 days in 85% of collegiate athletes 
recovering from their first concussion. However, variability is considerable as RTP can be 
delayed for a month or longer3, 192. Indeed, a first case report on a knocked-out boxer 
suggested that the time period with high CSF NF-L levels as a sign of ongoing axonal 
damage and dysfunction was extended over several months,191 and much longer than 
previously envisioned. Concomitant injuries to other body regions and depression can also 
delay RTP. Rest is also a frequent recommendation by emergency care physicians to 
patients recovering from a mild TBI due to external causes other than sports. However, 
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clinical management and follow-up of patients treated for mild TBI varies depending on 
factors such as emergency department´s policy, the treating physician, and identification of 
risk factors for delayed recovery. Concerns about this approach to concussion management 
include the lack of precise definitions of rest, ambiguities in its implementation, and 
evidence that durations of rest longer than 2-3 days may be deleterious193. To this point, 
translational research indicates that gradual introduction of exercise promotes 
neuroplasticity after concussion194.  
 
[H2]Persistent symptoms of CTE  
With sparse prospective, longitudinal studies of athletes exhibiting persistent symptoms 
associated with repeat sport-related concussion and/or repetitive head impacts; there is a 
lack of evidenced-based guidelines for either diagnosis or clinical management. Thus, 
current knowledge on clinical decision-making relies on retrospective clinical histories in 
neuropathologically confirmed cases of CTE102.  
 
For development of late life symptoms of mood and cognitive impairment, age of the 
athlete in relation to the typical playing career duration in the sport may be relevant195. 
Further, the position played by the athlete and the number of years played as a professional 
and in college provides an index of exposure to repetitive head impacts that may correlate 
with biomarker evidence of brain injuries182. More detailed neurological and 
neuropsychological assessments together with MRI using advanced sequences may 
identify evidence of brain damage that may guide whether to consider recommending an 
athlete to retire from the sport.  
 
In general, after taking into consideration the aforementioned factors, many clinicians 
would advise an athlete to retire from contact sports after sustaining multiple concussions 
especially if the injuries were temporally contiguous, i.e. within a single season. However, 
the evidence base for reaching this decision is weak and there is concern that long 
exposure to repetitive head impacts is sufficient to initiate a tau-based neurodegenerative 
process that is self-perpetuating. With a latent period estimated to be 8 to 10 years, the 
initial, pre-clinical stage of CTE is thought to be undetected by conventional imaging or 
clinical assessments196. The dilemma for the clinician and athlete is that current evidence 
does not permit estimation of the threshold of exposure for initiating this 
neurodegenerative process. Moreover, individual differences in genotype, medical and 
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social history, and other vulnerabilities may predispose to CTE. Recently developed tau 
ligands for PET imaging in Alzheimer’s disease can estimate the burden of tau in cerebral 
cortex, but validation of this technique in individuals at high risk for CTE is pending. In 
concert with other brain imaging modalities, fluid biomarkers, and monitoring 
neurobehavioral changes, it may soon be possible to identify CTE in a preclinical stage.  
 
[H1]Quality of life 
Life satisfaction following TBI may vary over time and is associated with multiple factors. 
Due to a dose-response relationship, levels of cognitive and physical disability are related 
to injury severity.197 However, besides injury severity, contextual factors such as income, 
mood, fatigue and social participation predict outcome too.198, 199  
 
Shortly post injury patients typically report low life satisfaction with a gradual 
improvement over the years. Locus of control, or the degree to which individuals believe 
that their health is controlled by factors within the person or external factors (outside the 
person), is related to health related quality of life after TBI (HR-QoL).200 An external 
oriented locus of control is negatively related to HR-QoL. Locus of control, self-efficacy 
and coping are intertwined concepts that may serve as potential targets to improve HR-
QoL. 12 months after mild TBI, symptoms and quality of life are similar to that of 
controls.201 However, over time a loss of life roles and prevalence of depression may 
hamper such an improvement or even cause a further decline of life satisfaction. Because 
the consequences of TBI may vary with varying contexts between individuals, insight into 
the impact of TBI as experienced by the patient, is required. Further, people with serious 
disabilities may report high satisfaction with life whereas caregivers and clinicians may 
question their quality of life. A lack of awareness but also a re-evaluation of what matters 
in life by the patient, may explain such a different perspective.  
 
[H1]Outlook 
Despite considerable advances, research on mild TBI and CTE is still in its infancy, with 
many gaps to be filled (Figure 6). These gaps range from improved knowledge on 
biophysical mechanisms, epidemiological data on the prevalence of CTE in contact sports 
athletes, as well as the precise molecular pathway from acute axonal injury to chronic and 
progressive neurodegeneration. 
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[H2]Mechanistic questions 
[H3]Which trauma forces cause brain damage in TBI and trigger CTE? 
Axonal injury is likely the central mechanism in TBI, which is accompanied by other 
changes such as inflammation, energy crisis and oxidative stress. However, further 
research is needed to resolve why axons are differentially vulnerable to trauma compared 
with other structures, and if injured axons with failed axonal transport recover and restore 
normal transport function. Further, the relationship between the extent of axonal injury and 
recovery rate or development of PCS after a single mild TBI episode is not known. 
Similarly, little is known on how many, or how severe, repeated TBIs are needed to initiate 
the neurodegeneration of CTE. Further, it is uncertain whether blast-related TBI and CTE 
in military personnel is due to brain damage caused by the blast overpressure, or whether 
the blast wind gives a detrimental acceleration of the head with resulting axonal 
shearing202. _ENREF_194To resolve these questions, we need tools to quantify both the 
trauma forces and the neuronal damage in mild TBI and blast injuries. 
 
[H3]What governs recovery after acute concussion? 
Why a proportion of patients develop long-lasting PCS is unclear203. These patients might 
have more severe neuronal damage, or sustain damage related to the type of impact and 
localization, but the possible influences of psychogenic or psychosocial mechanisms 
remain to be examined.  
 
[H3]What is the risk for CTE among contact sports athletes? 
Although repetitive sub-concussive head impacts are thought to initiate the 
neurodegenerative process leading to CTE196, the number of known CTE cases is limited, 
and it is not known what percentage of the very high number of individuals participating in 
contact sports will develop CTE. Thus, longitudinal epidemiological studies in contact 
sports athletes are needed to learn how frequent CTE is, as well as its relation to number 
and severity of concussions, length of career and similar risk factors. Furthermore, it will 
also be important to examine which factors govern resiliency to CTE and resolve the 
possible influence on CTE risk of psychosocial factors such as alcohol and drug abuse, 
obesity, diabetes and hypertension. 
 
[H3]What is the role of CTE pathology and does it propagate in the brain? 
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Recent preclinical discoveries suggest that repetitive concussive and/or sub-concussive 
brain injuries initiate tau pathology that then spreads to adjacent neurons in the absence of 
ongoing triggering factors204. However, we do not know if tau aggregates after TBI play a 
pathophysiological causal role in delayed neurodegeneration and development of CTE, or 
are they simply a marker of prior injury. Indeed, one neuropathology study on blast TBI in 
veterans report axonal, but no tau pathology, even in cases with long survival after blast,205 
and another report distinct astroglial scarring with dense astrogliosis in several brain areas, 
but no or minimal tau pathology.206 Further studies, especially longitudinal biomarker and 
neuropathology studies, correlating different types of pathology in affected brain regions 
with disease stage in CTE cases, will be valuable to understand whether tau pathology is 
the end step (or bystander) in the history of dysfunctional neurons rather than the cause of 
symptoms, and whether CTE progression is due to stereotypic between-neuron spreading 
of tau pathology following neuronal networks, or whether the disease simply affects an 
increasing number of brain regions with increasing severity. 
 
[H3]What is the role of amyloid plaques in CTE? 
Involvement of brain Aβ mis-metabolism and aggregation in after TBI is supported by 
animal experimental studies on rotational TBI showing sequential accumulation of APP, 
up regulation of the secretases and Aβ generation with formation of diffuse amyloid 
plaques66, 207. It is unclear how TBI induce Aβ oligomerization and aggregation, if Aβ 
oligomers cause toxicity in the setting of TBI, and whether Aβ plaques and intra-axonal Aβ 
depositions play pathophysiologically causal roles in the increased risk of Alzheimer’s 
disease. Tools that include CSF measurements and amyloid PET are available to monitor 
APP and Aβ metabolism and aggregation in patients. Application of these biomarkers in 
longitudinal studies will resolve the question whether Aβ aggregation is involved in CTE 
pathogenesis, or whether it is a bystander of neuronal damage and degeneration. 
  
[H3]Can we find an objective measure for neuronal damage in mild TBI? 
Some argue that the term concussion should be abandoned due to its vague definition and 
variable symptoms without any clinically identifiable pathological substrate208. 
Accordingly, there is an unmet need for biomarkers to identify and monitor axonal damage 
in mild TBI. However, the most studied blood biomarker, S100B, shows poor specificity to 
predict intracranial pathology by CT in mild TBI with many cases with false positive 
S100B results209. Further, S100B is present in peripheral organs, e.g. adipose tissue and 
27 
 
chondrocytes210, making it responsive to peripheral injuries and multi-trauma, further 
limiting its clinical usefulness. Given that the central mechanism in TBI is axonal damage, 
fluid biomarkers reflecting this type of damage may be useful. Ultrasensitive techniques to 
measure the axonal proteins tau178, 181 and NFL179, 182 in blood samples have been 
developed, but these biomarkers need evaluation in further clinical studies. 
 
[H3]Can we find tools to identify CTE in the clinic? 
Symptoms associated with CTE may be difficult to differentiate not only from Alzheimer’s 
disease and Parkinson’s disease but also from PCS and depression in younger patients211. 
Thus, both from a clinical perspective and for clinical studies on CTE pathogenesis, 
diagnostic tools are highly desirable. For Alzheimer’s disease, a number of biomarkers are 
by hand, including amyloid PET and CSF A42, both reflecting cortical -amyloid 
deposition212, the CSF biomarkers total tau and NFL reflecting damage to neuronal axons 
and phosphorylated tau protein that correlates with amount of cortical tau pathology141. In 
addition, recent developments have resulted in promising ligands for tau PET imaging, to 
visualize tau pathology directly in patients213. Given the similarity in pathology between 
Alzheimer’s disease and CTE, these biomarkers are top candidate CTE markers, but there 
are as yet no clinical biomarker studies on patients with suspected CTE pathology. 
 
 [H2]Prevention 
Guidelines for return to play have been proposed by the American Academy of 
Neurology214. These state that a concussed athlete should not return to play with persistent 
post-concussion symptoms at rest or with exertion, reduced academic or sports 
performance, abnormal neurological exam, neuropsychological test findings, or CT/MRI 
findings indicating increased risk214. Strict compliance with these guidelines by field and 
ringside physicians may reduce both short and long term suffering for contact sport 
athletes.  
 
Following international consensus criteria on concussion in sports, an athlete diagnosed 
with concussion should not be allowed by the physician or other licensed health provider to 
return to play on the day of injury3. Due to the nature of the sport, this is not easily applied 
in boxing, where an alternative to secure the well being of the contenders is to introduce 
rules not allowing head blows. Further, the Word Medical Association (WMA) 
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recommended the general ban of boxing in 2005, 215 based on the risk for brain damage 
and that the basic intent of boxing is to knock the opponent unconscious. However, the 
liability lies on the shoulders of sports organizations and governments to regulate rules in a 
way that minimizes risk for chronic brain damage for athletes, especially for those who are 
underaged. 
 
[H2]Emerging treatments 
Factors such as the marked phenotypic heterogeneity (anatomic, physiologic, and genetic) 
across injury severity, and limitations of current outcome assessment tools, have hindered 
the development of new therapies in TBI216. Furthermore, successful translation of new 
therapies to patients has been problematic despite the implementation of carefully designed 
multi-center randomized controlled trials217-219; accordingly, new clinical trial design, such 
as comparative effectiveness, might help to define optimal care and facilitate successful 
RCTs220. Despite these challenges, several novel therapies merit discussion.  
 
Cerebral edema, with resultant intracranial hypertension, has always been a key therapeutic 
target for severe TBI, but recent evidence suggests that brain edema could play a part 
across the injury spectrum221. Treatment of severe brain edema has traditionally been 
reactionary—via cerebrospinal fluid drainage, administration of osmolar agents, and/or 
craniectomy. Now, exploratory studies suggest new molecularly guided approaches to 
prevent its development. Emerging treatments such as glibenclamide targeting sulfonylurea 
receptor-1-mediated ion channel opening are in Phase II clinical trials (NCT01454154)222. 
Similarly, inhibition of aquaporin-4-mediated edema accumulation either directly or via 
blocking a cascade of events triggered by high mobility box-1 protein release and toll-like 
receptor activation is in pre-clinical testing223. Such approaches could improve care. 
 
Regarding therapy for mild TBI, several approaches for treatment are under investigation. 
A recent report suggests that hyperthermia (39°C) at the time of injury may magnify 
secondary damage and initiate degenerative processes such as CTE, with rapid 
normalization of body temperature being neuroprotective224. Further, recent pre-clinical 
studies suggest that acute accumulation and spread of a toxic cis-phosphorylated tau 
protein (cis P-tau) isomer may disrupt axonal microtubule networks and leas to apoptosis, 
while treatment with a monoclonal antibody against cis P-tau prevented its spread and 
improved outcome225. Last, cellular therapies may improve outcome by either aiding in the 
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creation of new circuitry or expressing trophic factors that are neuroprotective or 
regenerative. A Phase I study of autologous BMMNCs in children with severe TBI 
suggested that this approach might be feasible, safe, and associated with reduced treatment 
intensity226. 
  
 [H2]Fostering clinical research on TBI and CTE 
To improve our understanding of TBI and CTE pathogenesis, we need large longitudinal 
clinical studies combining clinical evaluations with genetic, imaging, biomarker and 
genetic data. As an example from other areas in clinical neuroscience, the Alzheimer's 
Disease Neuroimaging Initiative (ADNI) has had a vast impact on the understanding of 
Alzheimer’s disease227. For acute TBI, the prospective Transforming Research and Clinical 
Knowledge in Traumatic Brain Injury (TRACK-TBI) study in the US (NCT02119182) and 
the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain 
Injury (CENTER-TBI) study in Europe  (NCT02210221) are two prospective 
observational studies across the TBI severity spectrum (including mild TBI) examines 
clinical, imaging, genetic and blood biomarkers in the acute phase with longitudinal 
clinical follow-up, with the goals to improve methods for diagnosis and prognosis, refine 
outcome assessment and TBI care. For CTE, the Understanding Neurologic Injury and 
Traumatic Encephalopathy (UNITE) study228 is a retrospective clinic-pathological study 
aiming at investigate the validity of recently proposed clinical criteria102 and to identify 
clinical features that improve prediction of CTE pathology, and the Diagnose CTE 
Research Project is a multicenter, prospective longitudinal study evaluating clinical criteria 
for the diagnosis of TES as well as fluid and imaging biomarkers for CTE with the aim to 
enable diagnosing CTE in living individuals. These, and other, clinical studies are likely to 
improve our understanding of the pathophysiology, and the ability to ide mithe  
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Box 1. Classification of traumatic brain injury 
[H1]Mild TBI 
 Normal structural brain imaging 
 Loss of consciousness lasting 0-30 min  
 Altered mental state lasting ≤24 h  
 ≤1 day of post-trauma amnesia 
 Glasgow Coma Scale99 score of 13-15‡ 
[H1]Moderate TBI 
 Normal or abnormal structural brain imaging 
 Loss of consciousness lasting 30 min to 24 h 
 Altered mental state* lasting >24 h  
 1-7 days of post-trauma amnesia 
 Glasgow Coma Scale99 score of 9-12‡ 
[H1]Severe TBI 
 Normal or abnormal structural brain imaging 
 Loss of consciousness lasting > 24 h 
 Altered mental state* lasting >24 h  
 >7 days of post-trauma amnesia 
 Glasgow Coma Scale99 score of <9‡ 
 
Classification presented by the Department of Veterans Affairs (VA) and the Department of 
Defense (DoD) concussion/mTBI Working Group 2  
‡Best score in the first 24 h after trauma. 
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Box 2.  Conditions associated with TBI 
 
[H1]Sub-concussive head trauma 
 Head traumas that do not result in any subjective or objective symptoms 
 Whether repeated sub-concussive head traumas in contact sports add to the risk of developing 
CTE is currently unknown 
[H1] Repetitive mild TBI 
 Repeated episodes of concussion or mild TBI (Box 1) 
 Primarily experienced by contact sports athletes and in military personnel exposed to 
combat 
 Believed to initiate the self-propagating chronic neurodegenerative disorder CTE 
[H1] Post-concussive syndrome (PCS) 
 Also known as post-concussion disorder (PCD) 
 Mild TBI that persists beyond the expected recovery period (>3 months) 
 Nonspecific subjective symptoms, such as headache, fatigue, dizziness, poor concentration, 
sleep disturbances, anxiety, irritability and depressed mood 
 ~10-15% of individuals with concussion develop chronic symptoms 
[H1] Chronic traumatic encephalopathy (CTE) 
 Chronic neurodegenerative disorder initiated by repeated head trauma 
 The clinical counterpart to CTE, while not fully defined, has been termed traumatic 
encephalopathy syndrome (TES) 
 Both the clinical and pathological syndromes were first described in retired professional 
boxers and are now also recognized in athletes involved in many different contact sports 
and in military veterans 
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Box 3. Sports-related concussion 
Today, concussion in sports is diagnosed based on subjective symptoms. According to 
consensus diagnostic criteria, sports-related concussion (SRC)3, is a “transient disturbance 
of brain function due to a sports-related blow to the head or other body region”, causing 
acceleration of the head followed by onset of post-concussion symptoms, including 
somatic, cognitive, and emotional domains. Although loss of consciousness occurs in 
<10% of SRCs3, these injuries (and non-sports mild TBI) are often followed immediately 
(or within minutes to hours) by onset of one or more post-concussion symptoms, including 
headaches, dizziness, unstable balance, fatigue, nausea, blurred vision, sleep disturbance, 
and cognitive deficit such as memory or concentration problems. Symptoms of anxiety or 
depression may also emerge.  
 
Many athletic programs in the United States conduct pre-season “baseline” assessments 
that measure self-reported symptoms, balance and cognitive performance on standard tests 
often administered using computers and interpreted in relation to normative data. 
Following SRC, the clinician repeats this assessment to identify and grade the severity of 
PCS and cognitive deficit relative to baseline. Post-concussion symptoms and cognitive 
performance are monitored while the athlete completes a concussion management 
program. Loss of consciousness and post-traumatic amnesia duration (if present), number 
and severity of acute post-concussion symptoms predict time for recovery, which is often 
measured by the interval until the player is cleared to return to play192. 
 
Modifiers of the effects of concussion include age; young adolescents and children are at 
risk for slower recovery than college and professional athletes whose symptoms typically 
resolve within two weeks3. Prior SRC is considered to be a risk factor for prolonged 
recovery, but the evidence is mixed3. Similarly, some but not all studies indicate that 
females have a longer trajectory for resolution of PCS than males3. Similar to non-sports-
mTBI, pre-existing neuropsychiatric conditions may complicate recovery from SRC229. 
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Figure 1. Types of forces in mild TBI.  
The central mechanism for neuronal damage in mild traumatic brain injury (TBI) is 
acceleration and deceleration biomechanical forces that cause strain and shearing forces on 
the long axons in the brain, resulting in diffuse axonal injury. a | Linear (translational) 
acceleration occurs from forces making the head move in the anterior-posterior direction. b 
| Another force is rotational (angular) acceleration, which result from forces making the 
head to rotate sideways. c | Finally, impact deceleration is when the head forcefully 
decelerates, e.g. when an athlete’s head hits the ground. The figure represents schematic 
examples of different types of forces, while many TBIs are combinations of the above.  
 
Figure 2. Tau pathology in chronic traumatic encephalopathy. 
a | Tau pathology typically is strikingly irregular perivascular pattern (arrows) with dense 
patches located at the depths of the cortical sulci.  
b | Higher magnification of A, showing PHF-tau immunoreactive perivascular NFTs 
(arrows). 
 
Figure 3. Traumatic axonal injury in TBI. 
Traumatic axonal injury involves a complex set of pathophysiological events, which have 
been partially characterized. Rapid mechanical stretch, for example, can result in 
microtubule disruption (the nature of which is unclear) and impairs axonal transport with 
varicosity formation. Membrane leakage can involve frank membrane rupture, transient 
poration, or loss of ion channel permeation selectivity. The net effects of these changes can 
be axonal disconnection and aberrant co-localization of amyloid-beta (Aβ) that is the main 
component of amyloid plaques in Alzheimer’s disease, and is generated by sequential 
cleavage of amyloid precursor protein (APP) by the enzymes β-secretase (BACE) and 
presenilin 1 (PS1). Rapid mechanical stretch or injury can also induce a cascade beginning 
with membrane leakage and leading to intra-axonal calcium elevation, calpain- caspase-
mediated spectrin proteolysis, neurofilament compaction and axonal collapse. 
 
Figure 4. Diffusion Tensor Imaging for assessment of traumatic axonal injury 
A | After concussive or mild traumatic brain injury (TBI), abnormalities such as reduced 
diffusion anisotropy that were not detected using conventional MRI sequences (panels 1-3) 
were apparent using diffusion tensor imaging (DTI) (panel 4). Red arrows point to areas of 
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reduced anisotropy, indicated by less bright signal compared to the contralateral side. From 
Arfanakis et al American Journal of Neuroradiology 2002 fig 4.  
B | Radiological-pathological correlation between reduction in anisotropy and number of 
injured axons in a mouse model of TBI. From Brody et al Handbook of Clinical Neurology 
2015 Fig 17.8. Varying severities of controlled cortical impact traumatic brain injury were 
performed in mice at 1.0, 1.5, and 2.0 mm depth from the cortical surface. 24 hours later, 
mice were scanned with DTI to assess changes in relative anisotropy in the peri-
contusional brain white matter region (y-axis) and then the number of amyloid precursor 
protein (APP) stained injured axons was counted in histological sections corresponding to 
the same peri-contusional brain white matter regions. This study found a linear relationship 
between decreased anisotropy and increased traumatic axonal injury.  
C | Reduced relative anisotropy, indicated by less bright green color (red arrows), 
abnormalities detected using DTI (panels 1 and 2) in bilateral orbitofrontal white matter 
after blast-related concussive TBI in a US Military service member. These abnormalities 
were not detected with conventional T2 weighted MRI (panels 3 and 4) or CT (not shown). 
Color indicates primary direction of white matter tracts as detected by DTI: green indicates 
anterior-posterior, red indicates right-left, blue indicates rostral-caudal. From C.L. Mac 
Donald & D.L. Brody, unpublished data.  
D | High spatial and angular resolution DTI. using 1.25 x 1.25 x 1.25 mm voxels in a 
normal control subject without abnormalities. With high spatial resolution DTI, the 
individual white matter tracts can be more clearly distinguished from each other and from 
surrounding structures than with the lower spatial resolution (2.5 x 2.5 x 2.5 mm voxels) 
DTI used to produce the images in panels A and C. L Holleran and D.L. Brody, 
unpublished data.  
  
Figure 5. Repeated traumatic brain injuries and the window of vulnerability 
After traumatic brain injury, the brain has increased susceptibility for a new injury during 
the recovery phase, the “window of vulnerability”. A second mild injury before full 
resolution of pathophysiological changes following the first injury may add cumulative 
damage and prolong recovery from the second injury as compared with spacing the two 
injuries apart during a prolonged period of rest. Top: two traumatic brain injuries separated 
by an extended period of rest with complete normalization of pathophysiological changes. 
Bottom:  two traumatic brain injuries, where the second injury occurs during the phase of 
increased vulnerability with a prolonged recovery phase and incomplete normalization of 
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pathophysiological brain changes. This window of vulnerability to new brain injuries is the 
rationale for recommending contact sport athletes and extended return-to-play period after 
a concussion.  
 
Figure 6. Unknowns on the clinical and pathological pathways to chronic traumatic 
encephalopathy. 
Contact sports athletes are exposed for repeated concussions and/or sub-concussive blows, 
but most often recover quickly from symptoms. In an unknown proportion of at-risk 
individuals, repeated brain injury episodes are believed to initiate a chronic 
neurodegenerative disease that following a lag-phase of several years after the end of the 
contact sport career presents in the form of progressive cognitive, psychiatric and 
neurological symptoms and at autopsy primarily a tauopathy. Several unknowns require 
elucidation: The number, temporal distribution, and severity of traumatic brain injuries 
needed to initiate the disease process (1); why some patients develop long-term symptoms 
called post-concussion syndrome (PCS), and whether this syndrome is related to more-
severe neuronal damage or to early CTE pathology, and to which degree psychiatric 
predisposition and psychosocial factors contribute (2); whether clinically evident CTE 
symptoms are preceded by mild PCS or whether there is a clinically silent period (3); 
whether pathology slowly builds up at the multiple sites of brain damage, or whether it 
spreads from damaged to undamaged sites (4); and the degree to which ageing, other 
neurodegenerative pathologies, or other risk factors for brain pathology, contribute to the 
clinical presentation (5). 
 
 
36 
 
 
37 
 
 REFERENCES 
 
1. Cassidy, J.D. et al. Incidence, risk factors and prevention of mild traumatic brain 
injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic 
Brain Injury. J Rehabil Med, 28-60 (2004). 
2. Management of Concussion/m, T.B.I.W.G. VA/DoD Clinical Practice Guideline 
for Management of Concussion/Mild Traumatic Brain Injury. J Rehabil Res Dev 
46, CP1-68 (2009). 
3. McCrory, P. et al. Consensus statement on concussion in sport: the 4th 
International Conference on Concussion in Sport held in Zurich, November 2012. 
Br J Sports Med 47, 250-8 (2013). 
4. Medicine, A.C.o.R. Definition of mild traumatic brain injury. J Head Trauma 
Rehab 8, 86-87 (1993). 
5. West, T.A. & Marion, D.W. Current recommendations for the diagnosis and 
treatment of concussion in sport: a comparison of three new guidelines. J 
Neurotrauma 31, 159-68 (2014). 
6. Meares, S. et al. The prospective course of postconcussion syndrome: the role of 
mild traumatic brain injury. Neuropsychology 25, 454-65 (2011). 
7. Ponsford, J., Cameron, P., Fitzgerald, M., Grant, M. & Mikocka-Walus, A. Long-
term outcomes after uncomplicated mild traumatic brain injury: a comparison with 
trauma controls. J Neurotrauma 28, 937-46 (2011). 
8. Silverberg, N.D. & Iverson, G.L. Etiology of the post-concussion syndrome: 
Physiogenesis and Psychogenesis revisited. NeuroRehabilitation 29, 317-29 (2011). 
9. Martland, H.S. Punch drunk. Journal of the American Medical Association 91, 
1103-1107 (1928). 
10. Millspaugh, J. Dementia pugilistica. US Naval Med Bull 35, 297-303 (1937). 
11. Critchley, M. Punch-drunk syndromes: the chronic traumatic encephalopathy of 
boxers. Hommage a Clovis Vincent (ed). Maloine, Paris (1949). 
12. Blennow, K., Hardy, J. & Zetterberg, H. The neuropathology and neurobiology of 
traumatic brain injury. Neuron 76, 886-99 (2012). 
13. Gandy, S. et al. Chronic traumatic encephalopathy: clinical-biomarker correlations 
and current concepts in pathogenesis. Mol Neurodegener 9, 37 (2014). 
14. Corsellis, J.A., Bruton, C.J. & Freeman-Browne, D. The aftermath of boxing. 
Psychol Med 3, 270-303 (1973). 
15. Stein, T.D. et al. Beta-amyloid deposition in chronic traumatic encephalopathy. 
Acta Neuropathol 130, 21-34 (2015). 
16. Omalu, B.I. et al. Chronic traumatic encephalopathy in a National Football League 
player. Neurosurgery 57, 128-34; discussion 128-34 (2005). 
17. McKee, A.C. et al. The first NINDS/NIBIB consensus meeting to define 
neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. 
Acta Neuropathol 131, 75-86 (2016). 
18. Hyder, A.A., Wunderlich, C.A., Puvanachandra, P., Gururaj, G. & Kobusingye, 
O.C. The impact of traumatic brain injuries: a global perspective. 
NeuroRehabilitation 22, 341-53 (2007). 
19. Peeters, W. et al. Epidemiology of traumatic brain injury in Europe. Acta 
Neurochirurgica 157, 1683-1696 (2015). 
20. Centers for Disease Control and Prevention. (National Center for Injury Prevention 
and Control; Division of Unintentional Injury Prevention, Atlanta, GA, 2015). 
21. Maas, A.I., Stocchetti, N. & Bullock, R. Moderate and severe traumatic brain injury 
in adults. Lancet Neurol 7, 728-41 (2008). 
38 
 
22. Whiteneck, G.G., Cuthbert, J.P., Corrigan, J.D. & Bogner, J.A. Risk of Negative 
Outcomes After Traumatic Brain Injury: A Statewide Population-Based Survey. J 
Head Trauma Rehabil 31, E43-54 (2016). 
23. Roozenbeek, B., Maas, A.I. & Menon, D.K. Changing patterns in the epidemiology 
of traumatic brain injury. Nature Reviews Neurology 9, 231-236 (2013). 
24. Coronado, V.G. et al. Trends in Sports- and Recreation-Related Traumatic Brain 
Injuries Treated in US Emergency Departments: The National Electronic Injury 
Surveillance System-All Injury Program (NEISS-AIP) 2001-2012. J Head Trauma 
Rehabil 30, 185-97 (2015). 
25. Fleminger, S., Oliver, D., Lovestone, S., Rabe-Hesketh, S. & Giora, A. Head injury 
as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial 
replication. Journal of Neurology, Neurosurgery & Psychiatry 74, 857-862 (2003). 
26. Nordström, P., Michaëlsson, K., Gustafson, Y. & Nordström, A. Traumatic brain 
injury and young onset dementia: A nationwide cohort study. Annals of Neurology 
75, 374-381 (2014). 
27. Plassman, B.L. et al. Documented head injury in early adulthood and risk of 
Alzheimer's disease and other dementias. Neurology 55, 1158-66 (2000). 
28. Gardner, R.C. & Yaffe, K. Epidemiology of mild traumatic brain injury and 
neurodegenerative disease. Molecular and Cellular Neuroscience 66, Part B, 75-80 
(2015). 
29. McCrory, P., Meeuwisse, W.H., Kutcher, J.S., Jordan, B.D. & Gardner, A. What is 
the evidence for chronic concussion-related changes in retired athletes: behavioural, 
pathological and clinical outcomes? British Journal of Sports Medicine 47, 327-330 
(2013). 
30. King, A.I. Fundamentals of impact biomechanics: Part I--Biomechanics of the 
head, neck, and thorax. Annu Rev Biomed Eng 2, 55-81 (2000). 
31. Young, L.A., Rule, G.T., Bocchieri, R.T. & Burns, J.M. Biophysical mechanisms 
of traumatic brain injuries. Semin Neurol 35, 5-11 (2015). 
32. Cloots, R.J., Gervaise, H.M., van Dommelen, J.A. & Geers, M.G. Biomechanics of 
traumatic brain injury: influences of the morphologic heterogeneities of the cerebral 
cortex. Ann Biomed Eng 36, 1203-15 (2008). 
33. McKee, A.C. et al. Chronic traumatic encephalopathy in athletes: progressive 
tauopathy after repetitive head injury. J Neuropathol Exp Neurol 68, 709-35 
(2009). 
34. Gennarelli, T.A. et al. Diffuse axonal injury and traumatic coma in the primate. Ann 
Neurol 12, 564-74 (1982). 
35. Pellman, E.J., Viano, D.C., Tucker, A.M., Casson, I.R. & Waeckerle, J.F. 
Concussion in professional football: reconstruction of game impacts and injuries. 
Neurosurgery 53, 799-812; discussion 812-4 (2003). 
36. Walilko, T.J., Viano, D.C. & Bir, C.A. Biomechanics of the head for Olympic 
boxer punches to the face. Br J Sports Med 39, 710-9 (2005). 
37. Atha, J., Yeadon, M.R., Sandover, J. & Parsons, K.C. The damaging punch. Br 
Med J (Clin Res Ed) 291, 1756-7 (1985). 
38. Oppenheimer, D.R. Microscopic lesions in the brain following head injury. Journal 
of Neurology, Neurosurgery, and Psychiatry 31, 299 (1968). 
39. Blumbergs, P.C. et al. Stalning af amyloid percursor protein to study axonal 
damage in mild head Injury. The Lancet 344, 1055-1056 (1994). 
40. McKee, A.C., Daneshvar, D.H., Alvarez, V.E. & Stein, T.D. The neuropathology 
of sport. Acta neuropathologica 127, 29-51 (2014). 
39 
 
41. Oppenheimer, D.R. Microscopic lesions in the brain following head injury. J 
Neurol Neurosurg Psychiatry 31, 299-306 (1968). 
42. McKee, A.C. et al. The spectrum of disease in chronic traumatic encephalopathy. 
Brain 136, 43-64 (2013). 
43. McKee, A.C. et al. TDP-43 proteinopathy and motor neuron disease in chronic 
traumatic encephalopathy. J Neuropathol Exp Neurol 69, 918-29 (2010). 
44. Bieniek, K.F. et al. Chronic traumatic encephalopathy pathology in a 
neurodegenerative disorders brain bank. Acta Neuropathol (2015). 
45. Smith, D.H., Hicks, R. & Povlishock, J.T. Therapy Development for Diffuse 
Axonal Injury. J Neurotrauma (2013). 
46. Blumbergs, P.C. et al. Staining of amyloid precursor protein to study axonal 
damage in mild head injury. Lancet 344, 1055-6 (1994). 
47. Blumbergs, P.C. et al. Topography of axonal injury as defined by amyloid 
precursor protein and the sector scoring method in mild and severe closed head 
injury. J Neurotrauma 12, 565-72 (1995). 
48. Smith, D.H. et al. Immediate coma following inertial brain injury dependent on 
axonal damage in the brainstem. J Neurosurg 93, 315-22 (2000). 
49. Magnoni, S. et al. Tau elevations in the brain extracellular space correlate with 
reduced amyloid-beta levels and predict adverse clinical outcomes after severe 
traumatic brain injury. Brain 135, 1268-80 (2012). 
50. Niogi, S.N. & Mukherjee, P. Diffusion tensor imaging of mild traumatic brain 
injury. J Head Trauma Rehabil 25, 241-55 (2010). 
51. Tang-Schomer, M.D., Johnson, V.E., Baas, P.W., Stewart, W. & Smith, D.H. 
Partial interruption of axonal transport due to microtubule breakage accounts for 
the formation of periodic varicosities after traumatic axonal injury. Exp Neurol 233, 
364-72 (2012). 
52. Christman, C.W., Grady, M.S., Walker, S.A., Holloway, K.L. & Povlishock, J.T. 
Ultrastructural studies of diffuse axonal injury in humans. J Neurotrauma 11, 173-
86 (1994). 
53. Gentleman, S.M., Nash, M.J., Sweeting, C.J., Graham, D.I. & Roberts, G.W. Beta-
amyloid precursor protein (beta APP) as a marker for axonal injury after head 
injury. Neurosci Lett 160, 139-44 (1993). 
54. Stone, J.R. et al. Impaired axonal transport and altered axolemmal permeability 
occur in distinct populations of damaged axons following traumatic brain injury. 
Exp Neurol 190, 59-69 (2004). 
55. Marmarou, C.R., Walker, S.A., Davis, C.L. & Povlishock, J.T. Quantitative 
analysis of the relationship between intra- axonal neurofilament compaction and 
impaired axonal transport following diffuse traumatic brain injury. J Neurotrauma 
22, 1066-80 (2005). 
56. Grady, M.S. et al. The use of antibodies targeted against the neurofilament subunits 
for the detection of diffuse axonal injury in humans. J Neuropathol Exp Neurol 52, 
143-52 (1993). 
57. Stone, J.R., Singleton, R.H. & Povlishock, J.T. Intra-axonal neurofilament 
compaction does not evoke local axonal swelling in all traumatically injured axons. 
Exp Neurol 172, 320-31 (2001). 
58. Povlishock, J.T. & Katz, D.I. Update of neuropathology and neurological recovery 
after traumatic brain injury. J Head Trauma Rehabil 20, 76-94 (2005). 
59. Shitaka, Y. et al. Repetitive closed-skull traumatic brain injury in mice causes 
persistent multifocal axonal injury and microglial reactivity. J Neuropathol Exp 
Neurol 70, 551-67 (2011). 
40 
 
60. Buki, A. & Povlishock, J.T. All roads lead to disconnection?--Traumatic axonal 
injury revisited. Acta Neurochir (Wien) 148, 181-93 (2006). 
61. Bennett, R.E. & Brody, D.L. Array tomography for the detection of non-dilated, 
injured axons in traumatic brain injury. J Neurosci Methods 245, 25-36 (2015). 
62. Blennow, K., de Leon, M.J. & Zetterberg, H. Alzheimer's disease. Lancet 368, 387-
403 (2006). 
63. Magnoni, S. & Brody, D.L. New perspectives on amyloid-beta dynamics after 
acute brain injury: moving between experimental approaches and studies in the 
human brain. Arch Neurol 67, 1068-73 (2010). 
64. Ikonomovic, M.D. et al. Alzheimer's pathology in human temporal cortex 
surgically excised after severe brain injury. Exp Neurol 190, 192-203 (2004). 
65. Roberts, G.W., Gentleman, S.M., Lynch, A. & Graham, D.I. beta A4 amyloid 
protein deposition in brain after head trauma. Lancet 338, 1422-3. (1991). 
66. Smith, D.H. et al. Accumulation of amyloid beta and tau and the formation of 
neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol 
Exp Neurol 58, 982-92 (1999). 
67. Brody, D.L. et al. Amyloid-beta dynamics correlate with neurological status in the 
injured human brain. Science 321, 1221-4 (2008). 
68. Schwetye, K.E. et al. Traumatic brain injury reduces soluble extracellular amyloid-
beta in mice: a methodologically novel combined microdialysis-controlled cortical 
impact study. Neurobiol Dis 40, 555-64 (2010). 
69. Olsson, A. et al. Marked increase of beta-amyloid(1-42) and amyloid precursor 
protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J 
Neurol 251, 870-6 (2004). 
70. Smith, D.H. et al. Brain trauma induces massive hippocampal neuron death linked 
to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor 
protein. Am J Pathol 153, 1005-10. (1998). 
71. Chen, X.H. et al. Long-term accumulation of amyloid-beta, beta-secretase, 
presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol 
165, 357-71 (2004). 
72. Tran, H.T., Laferla, F.M., Holtzman, D.M. & Brody, D.L. Controlled Cortical 
Impact Traumatic Brain Injury in 3xTg-AD Mice Causes Acute Intra-Axonal 
Amyloid-beta Accumulation and Independently Accelerates the Development of 
Tau Abnormalities. J Neurosci 31, 9513-25 (2011). 
73. Lambert, M.P. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are 
potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95, 6448-53 
(1998). 
74. Walsh, D.M. & Selkoe, D.J. A beta oligomers - a decade of discovery. J 
Neurochem 101, 1172-84 (2007). 
75. Shankar, G.M. et al. Amyloid-beta protein dimers isolated directly from 
Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-42 
(2008). 
76. Cleary, J.P. et al. Natural oligomers of the amyloid-beta protein specifically disrupt 
cognitive function. Nat Neurosci 8, 79-84 (2005). 
77. Walsh, D.M. et al. Naturally secreted oligomers of amyloid beta protein potently 
inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-9 (2002). 
78. Esparza, T.J. et al. Amyloid-beta oligomerization in Alzheimer dementia versus 
high-pathology controls. Ann Neurol 73, 104-19 (2013). 
41 
 
79. Gotz, J., Chen, F., van Dorpe, J. & Nitsch, R.M. Formation of neurofibrillary 
tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 
1491-5 (2001). 
80. Tran, H.T., Sanchez, L. & Brody, D.L. Inhibition of JNK by a Peptide Inhibitor 
Reduces Traumatic Brain Injury-Induced Tauopathy in Transgenic Mice. J 
Neuropathol Exp Neurol 71, 116-29 (2012). 
81. Loane, D.J., Kumar, A., Stoica, B.A., Cabatbat, R. & Faden, A.I. Progressive 
neurodegeneration after experimental brain trauma: association with chronic 
microglial activation. J Neuropathol Exp Neurol 73, 14-29 (2014). 
82. Smith, C. Review: the long-term consequences of microglial activation following 
acute traumatic brain injury. Neuropathol Appl Neurobiol 39, 35-44 (2013). 
83. Aguzzi, A., Barres, B.A. & Bennett, M.L. Microglia: scapegoat, saboteur, or 
something else? Science 339, 156-61 (2013). 
84. Kumar, A., Alvarez-Croda, D.M., Stoica, B.A., Faden, A.I. & Loane, D.J. 
Microglial/macrophage polarization dynamics following traumatic brain injury. J 
Neurotrauma (2015). 
85. Helmy, A., Carpenter, K.L., Menon, D.K., Pickard, J.D. & Hutchinson, P.J. The 
cytokine response to human traumatic brain injury: temporal profiles and evidence 
for cerebral parenchymal production. J Cereb Blood Flow Metab 31, 658-70 
(2011). 
86. Helmy, A. et al. Recombinant human interleukin-1 receptor antagonist in severe 
traumatic brain injury: a phase II randomized control trial. J Cereb Blood Flow 
Metab 34, 845-51 (2014). 
87. Hall, E.D., Vaishnav, R.A. & Mustafa, A.G. Antioxidant therapies for traumatic 
brain injury. Neurotherapeutics 7, 51-61 (2010). 
88. Ji, J. et al. Lipidomics identifies cardiolipin oxidation as a mitochondrial target for 
redox therapy of brain injury. Nat Neurosci 15, 1407-13 (2012). 
89. Loane, D.J. & Kumar, A. Microglia in the TBI brain: The good, the bad, and the 
dysregulated. Exp Neurol (2015). 
90. Davidson, J., Cusimano, M.D. & Bendena, W.G. Post-Traumatic Brain Injury: 
Genetic Susceptibility to Outcome. Neuroscientist 21, 424-41 (2015). 
91. Huang, Y., Weisgraber, K.H., Mucke, L. & Mahley, R.W. Apolipoprotein E: 
diversity of cellular origins, structural and biophysical properties, and effects in 
Alzheimer's disease. J Mol Neurosci 23, 189-204 (2004). 
92. Poirier, J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's 
disease. Trends Neurosci 17, 525-30 (1994). 
93. Verghese, P.B., Castellano, J.M. & Holtzman, D.M. Apolipoprotein E in 
Alzheimer's disease and other neurological disorders. Lancet Neurol 10, 241-52 
(2011). 
94. Bennett, R.E. et al. Human apolipoprotein E4 worsens acute axonal pathology but 
not amyloid-beta immunoreactivity after traumatic brain injury in 3xTG-AD mice. 
J Neuropathol Exp Neurol 72, 396-403 (2013). 
95. Zeng, S. et al. Prognostic value of apolipoprotein E epsilon4 allele in patients with 
traumatic brain injury: a meta-analysis and meta-regression. Genet Test Mol 
Biomarkers 18, 202-10 (2014). 
96. Jordan, B.D. et al. Apolipoprotein E epsilon4 associated with chronic traumatic 
brain injury in boxing. JAMA 278, 136-40 (1997). 
97. Kutner, K.C., Erlanger, D.M., Tsai, J., Jordan, B. & Relkin, N.R. Lower cognitive 
performance of older football players possessing apolipoprotein E epsilon4. 
Neurosurgery 47, 651-7; discussion 657-8 (2000). 
42 
 
98. Kim, J., Yoon, H., Basak, J. & Kim, J. Apolipoprotein E in synaptic plasticity and 
Alzheimer's disease: potential cellular and molecular mechanisms. Mol Cells 37, 
767-76 (2014). 
99. Teasdale G, J.B. Assessment of coma and impaired consciousness. A practical 
scale. Lancet Neurol 2, 81-84 (1974). 
100. Teasdale G, M.A., Lecky F, Manley G, Stocchetti N, and Murray G. The Glasgow 
Coma Scale at 40 years: standing the test of time. Neurology 13, 844-854 (2014). 
101. Theadom, A. et al. Persistent problems 1 year after mild traumatic brain injury: a 
longitudinal population study in New Zealand. Br J Gen Pract 66, e16-23 (2016). 
102. Montenigro, P.H. et al. Clinical subtypes of chronic traumatic encephalopathy: 
literature review and proposed research diagnostic criteria for traumatic 
encephalopathy syndrome. Alzheimers Res Ther 6, 68 (2014). 
103. Schneider, H.J., Kreitschmann-Andermahr, I., Ghigo, E., Stalla, G.K. & Agha, A. 
Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal 
subarachnoid hemorrhage: a systematic review. Jama 298, 1429-38 (2007). 
104. Krahulik, D., Zapletalova, J., Frysak, Z. & Vaverka, M. Dysfunction of 
hypothalamic-hypophysial axis after traumatic brain injury in adults. J Neurosurg 
113, 581-4 (2010). 
105. Hannon, M.J. et al. Acute glucocorticoid deficiency and diabetes insipidus are 
common after acute traumatic brain injury and predict mortality. J Clin Endocrinol 
Metab 98, 3229-37 (2013). 
106. Aimaretti, G. et al. Traumatic brain injury and subarachnoid haemorrhage are 
conditions at high risk for hypopituitarism: screening study at 3 months after the 
brain injury. Clin Endocrinol (Oxf) 61, 320-6 (2004). 
107. Tanriverdi, F. & Kelestimur, F. Neuroendocrine Disturbances after Brain Damage: 
An Important and Often Undiagnosed Disorder. J Clin Med 4, 847-57 (2015). 
108. Klose, M. et al. Prevalence of posttraumatic growth hormone deficiency is highly 
dependent on the diagnostic set-up: results from The Danish National Study on 
Posttraumatic Hypopituitarism. J Clin Endocrinol Metab 99, 101-10 (2014). 
109. Kelly, D.F. et al. Prevalence of pituitary hormone dysfunction, metabolic 
syndrome, and impaired quality of life in retired professional football players: a 
prospective study. J Neurotrauma 31, 1161-71 (2014). 
110. Tanriverdi, F. et al. Kickboxing sport as a new cause of traumatic brain injury-
mediated hypopituitarism. Clin Endocrinol (Oxf) 66, 360-6 (2007). 
111. Wilkinson, C.W. et al. High prevalence of chronic pituitary and target-organ 
hormone abnormalities after blast-related mild traumatic brain injury. Front Neurol 
3, 11 (2012). 
112. Tanriverdi, F. & Kelestimur, F. Pituitary dysfunction following traumatic brain 
injury: clinical perspectives. Neuropsychiatr Dis Treat 11, 1835-43 (2015). 
113. Klose, M. & Feldt-Rasmussen, U. Hypopituitarism in Traumatic Brain Injury-A 
Critical Note. J Clin Med 4, 1480-97 (2015). 
114. Brody, D.L., Mac Donald, C.L. & Shimony, J.S. Current and future diagnostic tools 
for traumatic brain injury: CT, conventional MRI, and diffusion tensor imaging. 
Handb Clin Neurol 127, 267-75 (2015). 
115. Yuh, E.L. et al. Magnetic resonance imaging improves 3-month outcome prediction 
in mild traumatic brain injury. Ann Neurol 73, 224-35 (2013). 
116. Moenninghoff, C. et al. Diffuse axonal injury at ultra-high field MRI. PLoS One 
10, e0122329 (2015). 
43 
 
117. Hulkower, M.B., Poliak, D.B., Rosenbaum, S.B., Zimmerman, M.E. & Lipton, 
M.L. A decade of DTI in traumatic brain injury: 10 years and 100 articles later. 
AJNR Am J Neuroradiol 34, 2064-74 (2013). 
118. Mac Donald, C.L., Dikranian, K., Bayly, P., Holtzman, D. & Brody, D. Diffusion 
tensor imaging reliably detects experimental traumatic axonal injury and indicates 
approximate time of injury. J Neurosci 27, 11869-76 (2007). 
119. Mac Donald, C.L. et al. Detection of blast-related traumatic brain injury in U.S. 
military personnel. N Engl J Med 364, 2091-100 (2011). 
120. Niogi, S.N. et al. Structural dissociation of attentional control and memory in adults 
with and without mild traumatic brain injury. Brain 131, 3209-21 (2008). 
121. Magnoni, S. et al. Quantitative assessments of traumatic axonal injury in human 
brain: concordance of microdialysis and advanced MRI. Brain 138, 2263-77 
(2015). 
122. Nieuwenhuys, R., Voogd, J. & van Huijzen, C. The Human Central Nervous 
System (Springer, 2008). 
123. Grossman, E.J. et al. Thalamus and cognitive impairment in mild traumatic brain 
injury: a diffusional kurtosis imaging study. J Neurotrauma 29, 2318-27 (2012). 
124. Morey, R.A. et al. Effects of chronic mild traumatic brain injury on white matter 
integrity in Iraq and Afghanistan war veterans. Hum Brain Mapp 34, 2986-99 
(2013). 
125. Presson, N. et al. An exploratory analysis linking neuropsychological testing to 
quantification of tractography using High Definition Fiber Tracking (HDFT) in 
military TBI. Brain Imaging Behav 9, 484-99 (2015). 
126. Wang, X. et al. Diffusion basis spectrum imaging detects and distinguishes 
coexisting subclinical inflammation, demyelination and axonal injury in 
experimental autoimmune encephalomyelitis mice. NMR Biomed 27, 843-52 
(2014). 
127. Maudsley, A. et al. Distributions of MR Diffusion and Spectroscopy Measures with 
Traumatic Brain Injury. J Neurotrauma (2014). 
128. Vagnozzi, R. et al. Assessment of metabolic brain damage and recovery following 
mild traumatic brain injury: a multicentre, proton magnetic resonance spectroscopic 
study in concussed patients. Brain 133, 3232-42 (2010). 
129. Irimia, A. & Van Horn, J.D. Functional neuroimaging of traumatic brain injury: 
advances and clinical utility. Neuropsychiatr Dis Treat 11, 2355-65 (2015). 
130. Huang, M.X. et al. Single-subject-based whole-brain MEG slow-wave imaging 
approach for detecting abnormality in patients with mild traumatic brain injury. 
Neuroimage Clin 5, 109-19 (2014). 
131. Tarapore, P.E. et al. Resting state magnetoencephalography functional connectivity 
in traumatic brain injury. J Neurosurg 118, 1306-16 (2013). 
132. Huang, M.X. et al. Integrated imaging approach with MEG and DTI to detect mild 
traumatic brain injury in military and civilian patients. J Neurotrauma 26, 1213-26 
(2009). 
133. Lewine, J.D., Davis, J.T., Sloan, J.H., Kodituwakku, P.W. & Orrison, W.W., Jr. 
Neuromagnetic assessment of pathophysiologic brain activity induced by minor 
head trauma. AJNR Am J Neuroradiol 20, 857-66 (1999). 
134. Klunk, W.E. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and 
risk prediction for Alzheimer dementia. Neurobiol Aging 32 Suppl 1, S20-36 
(2011). 
135. Hong, Y.T. et al. Amyloid imaging with carbon 11-labeled Pittsburgh compound B 
for traumatic brain injury. JAMA Neurol 71, 23-31 (2014). 
44 
 
136. Scott, G. et al. Amyloid pathology and axonal injury after brain trauma. Neurology 
(2016). 
137. Scholl, M., Damian, A. & Engler, H. Fluorodeoxyglucose PET in Neurology and 
Psychiatry. PET Clin 9, 371-90, v (2014). 
138. Byrnes, K.R. et al. FDG-PET imaging in mild traumatic brain injury: a critical 
review. Front Neuroenergetics 5, 13 (2014). 
139. Okamura, N. et al. Advances in the development of tau PET radiotracers and their 
clinical applications. Ageing Res Rev (2016). 
140. Villemagne, V.L., Fodero-Tavoletti, M.T., Masters, C.L. & Rowe, C.C. Tau 
imaging: early progress and future directions. Lancet Neurol 14, 114-24 (2015). 
141. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and 
plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-44 (2010). 
142. Csuka, E. et al. IL-10 levels in cerebrospinal fluid and serum of patients with 
severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and 
blood-brain barrier function. J Neuroimmunol 101, 211-21 (1999). 
143. Kossmann, T. et al. Intrathecal and serum interleukin-6 and the acute-phase 
response in patients with severe traumatic brain injuries. Shock 4, 311-7 (1995). 
144. Blennow, K. et al. No neurochemical evidence of brain injury after blast 
overpressure by repeated explosions or firing heavy weapons. Acta Neurol Scand 
123, 245-51 (2011). 
145. Zetterberg, H. et al. Neurochemical aftermath of amateur boxing. Arch Neurol 63, 
1277-80 (2006). 
146. Buttram, S.D. et al. Multiplex assessment of cytokine and chemokine levels in 
cerebrospinal fluid following severe pediatric traumatic brain injury: effects of 
moderate hypothermia. J Neurotrauma 24, 1707-17 (2007). 
147. Kumar, R.G. et al. Acute CSF interleukin-6 trajectories after TBI: associations with 
neuroinflammation, polytrauma, and outcome. Brain Behav Immun 45, 253-62 
(2015). 
148. Zetterberg, H., Smith, D.H. & Blennow, K. Biomarkers of mild traumatic brain 
injury in cerebrospinal fluid and blood. Nat Rev Neurol 9, 201-10 (2013). 
149. Ost, M. et al. Initial CSF total tau correlates with 1-year outcome in patients with 
traumatic brain injury. Neurology 67, 1600-4 (2006). 
150. Rubenstein, R. et al. A novel, ultrasensitive assay for tau: potential for assessing 
traumatic brain injury in tissues and biofluids. J Neurotrauma 32, 342-52 (2015). 
151. Neselius, S. et al. CSF-biomarkers in Olympic boxing: diagnosis and effects of 
repetitive head trauma. PLoS ONE 7, e33606 (2012). 
152. Olsson, B., Zetterberg, H., Hampel, H. & Blennow, K. Biomarker-based dissection 
of neurodegenerative diseases. Prog Neurobiol (2011). 
153. Bohmer, A.E. et al. Neuron-specific enolase, S100B, and glial fibrillary acidic 
protein levels as outcome predictors in patients with severe traumatic brain injury. 
Neurosurgery 68, 1624-30; discussion 1630-1 (2011). 
154. Ross, S.A., Cunningham, R.T., Johnston, C.F. & Rowlands, B.J. Neuron-specific 
enolase as an aid to outcome prediction in head injury. Br J Neurosurg 10, 471-6 
(1996). 
155. Ramont, L. et al. Effects of hemolysis and storage condition on neuron-specific 
enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. 
Clin Chem Lab Med 43, 1215-7 (2005). 
156. Czeiter, E. et al. Brain injury biomarkers may improve the predictive power of the 
IMPACT outcome calculator. J Neurotrauma 29, 1770-8 (2012). 
45 
 
157. McMahon, P.J. et al. Measurement of the GFAP-BDP Biomarker for the Detection 
of Traumatic Brain Injury Compared to CT and MRI. J Neurotrauma (2014). 
158. Raby, C.A. et al. Traumatic brain injury increases beta-amyloid peptide 1-42 in 
cerebrospinal fluid. J Neurochem 71, 2505-9 (1998). 
159. Marklund, N. et al. Monitoring of beta-amyloid dynamics after human traumatic 
brain injury. J Neurotrauma 31, 42-55 (2014). 
160. Riederer, B.M., Zagon, I.S. & Goodman, S.R. Brain spectrin(240/235) and brain 
spectrin(240/235E): two distinct spectrin subtypes with different locations within 
mammalian neural cells. J Cell Biol 102, 2088-97 (1986). 
161. Pike, B.R. et al. Accumulation of non-erythroid alpha II-spectrin and calpain-
cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic 
brain injury in rats. J Neurochem 78, 1297-306 (2001). 
162. Pineda, J.A. et al. Clinical significance of alphaII-spectrin breakdown products in 
cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma 24, 354-66 
(2007). 
163. Farkas, O. et al. Spectrin breakdown products in the cerebrospinal fluid in severe 
head injury--preliminary observations. Acta Neurochir (Wien) 147, 855-61 (2005). 
164. Mondello, S. et al. alphaII-spectrin breakdown products (SBDPs): diagnosis and 
outcome in severe traumatic brain injury patients. J Neurotrauma 27, 1203-13 
(2010). 
165. Wilkinson, K.D. et al. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-
terminal hydrolase. Science 246, 670-3 (1989). 
166. Buki, A., Siman, R., Trojanowski, J.Q. & Povlishock, J.T. The role of calpain-
mediated spectrin proteolysis in traumatically induced axonal injury. J Neuropathol 
Exp Neurol 58, 365-75 (1999). 
167. Diaz-Arrastia, R. et al. Acute biomarkers of traumatic brain injury: relationship 
between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary 
acidic protein. J Neurotrauma 31, 19-25 (2014). 
168. Nylen, K. et al. Increased serum-GFAP in patients with severe traumatic brain 
injury is related to outcome. J Neurol Sci 240, 85-91 (2006). 
169. Okonkwo, D.O. et al. GFAP-BDP as an acute diagnostic marker in traumatic brain 
injury: results from the prospective transforming research and clinical knowledge in 
traumatic brain injury study. J Neurotrauma 30, 1490-7 (2013). 
170. Papa, L. et al. Time Course and Diagnostic Accuracy of Glial and Neuronal Blood 
Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and 
Without Mild Traumatic Brain Injury. JAMA Neurol 73, 551-60 (2016). 
171. Welch, R.D. et al. Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-
Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head 
Computed Tomography Findings in Patients with Suspected Mild or Moderate 
Traumatic Brain Injury. J Neurotrauma 33, 203-14 (2016). 
172. Metting, Z., Wilczak, N., Rodiger, L.A., Schaaf, J.M. & van der Naalt, J. GFAP 
and S100B in the acute phase of mild traumatic brain injury. Neurology 78, 1428-
33 (2012). 
173. Unden, J., Ingebrigtsen, T., Romner, B. & Scandinavian Neurotrauma, C. 
Scandinavian guidelines for initial management of minimal, mild and moderate 
head injuries in adults: an evidence and consensus-based update. BMC Med 11, 50 
(2013). 
174. Unden, L., Calcagnile, O., Unden, J., Reinstrup, P. & Bazarian, J. Validation of the 
Scandinavian guidelines for initial management of minimal, mild and moderate 
traumatic brain injury in adults. BMC Med 13, 292 (2015). 
46 
 
175. Siman, R. et al. A panel of neuron-enriched proteins as markers for traumatic brain 
injury in humans. J Neurotrauma 26, 1867-77 (2009). 
176. Siman, R. et al. Evidence That the Blood Biomarker SNTF Predicts Brain Imaging 
Changes and Persistent Cognitive Dysfunction in Mild TBI Patients. Front Neurol 
4, 190 (2013). 
177. Siman, R. et al. Serum SNTF Increases in Concussed Professional Ice Hockey 
Players and Relates to the Severity of Post-Concussion Symptoms. J Neurotrauma 
(2014). 
178. Randall, J. et al. Tau proteins in serum predict neurological outcome after hypoxic 
brain injury from cardiac arrest: results of a pilot study. Resuscitation 84, 351-6 
(2013). 
179. Gisslén, M. et al. Plasma concentration of the neurofilament light protein (NFL) is 
a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 
In press (2015). 
180. Zetterberg, H. et al. Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther 
5, 9 (2013). 
181. Shahim, P. et al. Blood biomarkers for brain injury in concussed professional ice 
hockey players. JAMA Neurol 71, 684-92 (2014). 
182. Oliver, J. et al. Serum Neurofilament Light in American Football Athletes Over the 
Course of a Season. J Neurotrauma (2015). 
183. Unden, J., Ingebrigtsen, T. & Romner, B. Scandinavian guidelines for initial 
management of minimal, mild and moderate head injuries in adults: an evidence 
and consensus-based update. BMC Med 11, 50 (2013). 
184. Jagoda AS, B.J., Bruns JJ Jr, et al, and the American College of Emergency 
Physicians, and the Centers for Disease Control and Prevention. Clinical policy: 
neuroimaging and decision making in mild traumatic brain injury in the acute 
setting. Ann Emerg Med 52 (2008). 
185. Levin HS, D.-A.R. Diagnosis, prognosis, and clinical management of mild 
traumatic brain injury. Lancet Neurol 14, 506-17 (2015). 
186. DiTommaso C, H.J., Lucas S, Dikmen S, Temkin N, Bell KR. Medication usage 
patterns for headache treatment after mild traumatic  brain injury. Headache 54, 
511-19 (2014). 
187. Bombardier CH, F.J., Temkin NR, Esselman PC, Barber J, Dikmen SS. Rates of 
major depressive disorder and clinical outcomes following traumatic brain injury. 
JAMA 303, 1938-45 (2010). 
188. Giza CC, H.D. The New Neurometabolic Cascade of Concussion. Neurosurgery 
75, S24–S33 (2014). 
189. Guskiewicz, K.M. et al. Cumulative effects associated with recurrent concussion in 
collegiate football players: the NCAA Concussion Study. JAMA 290, 2549-55 
(2003). 
190. Slobounov, S., Slobounov, E., Sebastianelli, W., Cao, C. & Newell, K. Differential 
rate of recovery in athletes after first and second concussion episodes. 
Neurosurgery 61, 338-44; discussion 344 (2007). 
191. Neselius, S., Brisby, H., Granholm, F., Zetterberg, H. & Blennow, K. Monitoring 
concussion in a knocked-out boxer by CSF biomarker analysis. Knee Surg Sports 
Traumatol Arthrosc 23, 2536-9 (2015). 
192. Meehan WP, M.R., Monuteaux MC, Stein CJ, Bachur RG. Early symptom burden 
predicts recovery after sport-related concussion. Neurology 83, 2204-10 (2014). 
47 
 
193. Thomas, D., Apps, JN, Hoffmann, RG, McCrea, M, Hammeke, T. Benefits of strict 
rest after acute concussion: A randomized controlled trial. Pediatrics 135, 213-23 
(2015). 
194. Leddy JJ, C.J., Baker JG, Wack DS, Pendergast DR, Zivadinov R, Willer B. 
Exercise treatment for postconcussion syndrome: a pilot study of changes in 
functional magnetic resonance imaging activation, physiology, and symptoms. J 
Head Trauma Rehabil 28, 241-9 (2013). 
195. Montenigro, P.H. et al. Cumulative Head Impact Exposure Predicts Later-Life 
Depression, Apathy, Executive Dysfunction, and Cognitive Impairment in Former 
High School and College Football Players. J Neurotrauma (2016). 
196. McKee, A.C. et al. The spectrum of disease in chronic traumatic encephalopathy. 
Brain 136, 43-64 (2013). 
197. Willemse-van Son, A.H., Ribbers, G.M., Verhagen, A.P. & Stam, H.J. Prognostic 
factors of long-term functioning and productivity after traumatic brain injury: a 
systematic review of prospective cohort studies. Clin Rehabil 21, 1024-37 (2007). 
198. Grauwmeijer, E., Heijenbrok-Kal, M.H. & Ribbers, G.M. Health-related quality of 
life 3 years after moderate to severe traumatic brain injury: a prospective cohort 
study. Arch Phys Med Rehabil 95, 1268-76 (2014). 
199. Willemse-van Son, A.H., Ribbers, G.M., Hop, W.C. & Stam, H.J. Community 
integration following moderate to severe traumatic brain injury: a longitudinal 
investigation. J Rehabil Med 41, 521-7 (2009). 
200. Wielenga-Boiten, J.E., Heijenbrok-Kal, M.H. & Ribbers, G.M. The Relationship of 
Health Locus of Control and Health-Related Quality of Life in the Chronic Phase 
After Traumatic Brain Injury. J Head Trauma Rehabil 30, 424-31 (2015). 
201. Andelic, N. et al. Trajectories of physical health in the first 5 years after traumatic 
brain injury. J Neurol 262, 523-31 (2015). 
202. Goldstein, L.E. et al. Chronic traumatic encephalopathy in blast-exposed military 
veterans and a blast neurotrauma mouse model. Sci Transl Med 4, 134ra60 (2012). 
203. DeKosky, S.T., Blennow, K., Ikonomovic, M.D. & Gandy, S. Acute and chronic 
traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol 9, 192-
200 (2013). 
204. Clavaguera, F., Goedert, M. & Tolnay, M. [Induction and spreading of tau 
pathology in a mouse model of Alzheimer's disease]. Med Sci (Paris) 26, 121-4 
(2010). 
205. Ryu, J. et al. The problem of axonal injury in the brains of veterans with histories 
of blast exposure. Acta Neuropathol Commun 2, 153 (2014). 
206. Shively, S.B. et al. Characterisation of interface astroglial scarring in the human 
brain after blast exposure: a post-mortem case series. Lancet Neurol 15, 944-53 
(2016). 
207. Johnson, V.E., Stewart, W. & Smith, D.H. Traumatic brain injury and amyloid-beta 
pathology: a link to Alzheimer's disease? Nat Rev Neurosci 11, 361-70 (2010). 
208. Sharp, D.J. & Jenkins, P.O. Concussion is confusing us all. Pract Neurol 15, 172-
86 (2015). 
209. Ingebrigtsen, T. et al. The clinical value of serum S-100 protein measurements in 
minor head injury: a Scandinavian multicentre study. Brain Inj 14, 1047-55 (2000). 
210. Haimoto, H., Hosoda, S. & Kato, K. Differential distribution of immunoreactive 
S100-alpha and S100-beta proteins in normal nonnervous human tissues. Lab 
Invest 57, 489-98 (1987). 
48 
 
211. Mez, J., Solomon, T.M., Daneshvar, D.H., Stein, T.D. & McKee, A.C. 
Pathologically Confirmed Chronic Traumatic Encephalopathy in a 25-Year-Old 
Former College Football Player. JAMA Neurol, 1-3 (2016). 
212. Blennow, K., Mattsson, N., Scholl, M., Hansson, O. & Zetterberg, H. Amyloid 
biomarkers in Alzheimer's disease. Trends Pharmacol Sci 36, 297-309 (2015). 
213. Eisenmenger, L.B. et al. Advances in PET Imaging of Degenerative, 
Cerebrovascular, and Traumatic Causes of Dementia. Semin Nucl Med 46, 57-87 
(2016). 
214. Giza, C.C. et al. Summary of evidence-based guideline update: evaluation and 
management of concussion in sports: report of the Guideline Development 
Subcommittee of the American Academy of Neurology. Neurology 80, 2250-7 
(2013). 
215. http://www.wma.net/en/30publications/10policies/b6/. (2005). 
216. Maas, A.I., Roozenbeek, B. & Manley, G.T. Clinical trials in traumatic brain 
injury: past experience and current developments. Neurotherapeutics 7, 115-26 
(2010). 
217. Andrews, P.J. et al. Hypothermia for Intracranial Hypertension after Traumatic 
Brain Injury. N Engl J Med 373, 2403-12 (2015). 
218. Nichol, A. et al. Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind 
randomised controlled trial. Lancet 386, 2499-506 (2015). 
219. Wright, D.W. et al. Very early administration of progesterone for acute traumatic 
brain injury. N Engl J Med 371, 2457-66 (2014). 
220. Kochanek, P.M. et al. Operation Brain Trauma Therapy: Approach to Modeling, 
Therapy Evaluation, Drug Selection, and Biomarker Assessments for a Multicenter 
Pre-Clinical Drug Screening Consortium for Acute Therapies in Severe Traumatic 
Brain Injury. J Neurotrauma (2015). 
221. Hasan, K.M. et al. Serial atlas-based diffusion tensor imaging study of 
uncomplicated mild traumatic brain injury in adults. J Neurotrauma 31, 466-75 
(2014). 
222. Walcott, B.P., Kahle, K.T. & Simard, J.M. Novel treatment targets for cerebral 
edema. Neurotherapeutics 9, 65-72 (2012). 
223. Laird, M.D. et al. High mobility group box protein-1 promotes cerebral edema after 
traumatic brain injury via activation of toll-like receptor 4. Glia 62, 26-38 (2014). 
224. Titus, D.J., Furones, C., Atkins, C.M. & Dietrich, W.D. Emergence of cognitive 
deficits after mild traumatic brain injury due to hyperthermia. Exp Neurol 263, 254-
62 (2015). 
225. Kondo, A. et al. Antibody against early driver of neurodegeneration cis P-tau 
blocks brain injury and tauopathy. Nature 523, 431-6 (2015). 
226. Liao, G.P. et al. Autologous bone marrow mononuclear cells reduce therapeutic 
intensity for severe traumatic brain injury in children. Pediatr Crit Care Med 16, 
245-55 (2015). 
227. Weiner, M.W. et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 
2004 to 2014. Alzheimers Dement 11, 865-84 (2015). 
228. Mez, J. et al. Assessing clinicopathological correlation in chronic traumatic 
encephalopathy: rationale and methods for the UNITE study. Alzheimers Res Ther 
7, 62 (2015). 
229. Ponsford J, C.P., Fitzgerald M, Grant M, Mikocka-Walus A. Long-term outcomes 
after uncomplicated mild traumatic brain injury: a comparision with trauma 
controls. J Neurotrauma 28, 937-46 (2011). 
 
49 
 
 
